Pusateri v. Secretary of Health and Human Services

In the United States Court of Federal Claims

OFFICE OF SPECIAL MASTERS

Filed: September 23, 2024

*********************

VICTORIA PUSATERI, *

*

Petitioner, * No. 16-467

*

v. * Special Master Gowen

*

SECRETARY OF HEALTH *

AND HUMAN SERVICES, *

*

Respondent. *

*********************

Scott W. Rooney, Nemes, Rooney P.C., Farmington Hills, MI, for petitioner.

Catherine E. Stolar, U.S. Dept. of Justice, Washington, D.C., for respondent.

DECISION1

On April 13, 2016, Victoria Pusateri (“petitioner”) filed a petition for compensation

under the National Vaccine Injury Compensation Program.2 Petition (ECF No. 1). Petitioner

alleges that the human papillomavirus (“HPV”) vaccine administered on February 18 and April

22, 2013 significantly aggravated her immunodeficiency disorder, inflammatory bowel

condition, esophagitis, bronchitis, and alopecia areata. Petition (“Pet.”) at 2-5. Based on a full

review of the evidence including medical records and expert reports, I find that petitioner has not

established by preponderant evidence that the HPV vaccine caused or significantly aggravated

any of her conditions and the petition must be DISMISSED.

1

Pursuant to the E-Government Act of 2002, see 44 U.S.C. § 3501 note (2012), because this opinion contains a

reasoned explanation for the action in this case, I am required to post it on the website of the United States Court of

Federal Claims. The court’s website is at http://www.uscfc.uscourts.gov/aggregator/sources/7. This means the

opinion will be available to anyone with access to the Internet. Before the opinion is posted on the court’s

website, each party has 14 days to file a motion requesting redaction “of any information furnished by that party:

(1) that is a trade secret or commercial or financial in substance and is privileged or confidential; or (2) that

includes medical files or similar files, the disclosure of which would constitute a clearly unwarranted invasion of

privacy.” Vaccine Rule 18(b). “An objecting party must provide the court with a proposed redacted version of the

decision.” Id. If neither party files a motion for redaction within 14 days, the opinion will be posted on the

court’s website without any changes. Id.

2

The National Vaccine Injury Compensation Program is set forth in Part 2 of the National Childhood Vaccine

Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755, codified as amended, 42 U.S.C. §§ 300aa-10 to 34

(2012) (hereinafter “Vaccine Act” or “the Act”). Hereinafter, individual section references will be to 42 U.S.C. §

300aa of the Act.

I. Procedural History

Petitioner filed a petition for compensation on April 13, 2016 and her petition was

accompanied by medical records. See Pet. Exhibits (“Exs.”) 1-10, 12. On December 14, 2017,

petitioner filed expert reports from John Santoro, D.O..3, a gastroenterologist, to support her

claim that the HPV vaccines caused petitioner to have ulcerative colitis and Marc David

Glashofer, M.D, M.S.4, to support her claim that petitioner’s alopecia was caused by the HPV

vaccines. Pet. Exs. 14, 15 (ECF Nos. 57, 59).

Respondent filed the Rule 4(c) report, recommending against compensation, arguing that

“the alleged development of petitioner’s symptoms is outside the accepted timeframe to

demonstrate vaccine causation or significant aggravation,” and that petitioner’s diagnosis of

Common Variable Immune Deficiency (“CVID”) and antibiotic use provide alternative causes

for petitioner’s symptoms. Respondent (“Resp.”) Report (“Rept.”) at 6-7 (ECF No. 64).

Respondent also filed an expert report from Randy Longman, M.D.5, a gastroenterologist, who

opined that petitioner’s underlying immune deficiency and repeated exposure to antibiotics

caused the exacerbation of her colitis. Resp. Ex. A at 5 (ECF No. 63).

3

Dr. John J. Santoro was a gastroenterologist in practice with Atlantic Gastroenterology. Pet. Ex. 14. He

unfortunately passed away during the course of this litigation. Dr. Santoro served as the Medical Director of Clinical

Research at Atlantic Gastroenterology Associates and was Director of the Hepatitis Treatment Center at the same

group. Id. After completing undergraduate at LaSalle College, he attended Philadelphia College of Osteopathic

Medicine and graduated in 1978. Pet. Ex. 14A at 2. Dr. Santoro completed a residency at the University of

Medicine and Dentistry at John F. Kennedy Memorial Hospital in 1981. Id. Dr. Santoro became a Fellow of

Gastroenterology at University of Medicine and Dentistry with the NJ School of Osteopathic Medicine and with the

Kennedy Memorial Hospitals. Id. at 3. He was board certified in Internal Medicine and Gastroenterology. Id. Dr.

Santoro was licensed to practice medicine in New Jersey and Pennsylvania. Id. As of the filing of his CV, Dr.

Santoro was a Clinical Associate Professor of Medicine at Rowan University of Osteopathic Medicine. Id. at 4.

Additionally, Dr. Santoro has authored or co-authored numerous medical articles on issues that affect the

gastrointestinal tract. Id. Dr. Santoro has provided his opinion in other vaccine cases, where he has been accepted

as an expert in gastroenterology. See e.g. B.E. v. Sec’y of Health & Human Servs., No. 15-1458V, 2019 WL

1560371 (Fed. Cl. Spec. Mstr. Feb. 26, 2019). Accordingly, for the purposes of this case, Dr. Santoro is accepted as

an expert in gastroenterology for this matter.

4

Dr. Marc D. Glashofer is a dermatologist in practice with The Dermatology Group in West Orange, New Jersey.

Pet. Ex. 15A. He attended the University of Maryland for his undergraduate degree and attended the George

Washington University School of Medicine and Health Services in Washington, D.C. Id. Dr. Glashofer completed

his residency in dermatology at Tulane University School of Medicine in New Orleans, Louisiana. Dr. Glashofer is

board certified in dermatology. He serves as a peer reviewer for the Journal of Dermatologic Treatment and Journal

of Drugs and Dermatology and is on the Clinical Research Advisory Council for the National Alopecia Areata

Foundation. Id. at 3. It does not appear that Dr. Glashofer has appeared as an expert in the Vaccine Program before,

however, he is a practicing dermatologist with expertise in the field. Accordingly, Dr. Glashofer is accepted as an

expert in dermatology in this matter.

5

Dr. Randy Longman is an assistant professor of gastroenterology and hepatology at at the Jill Robrts IBD Center at

Weill Cornell Medical Center in New York. Resp. Ex. B. He received his undergraduate degree from Yale

University and then received his medical degree from Cornell Medical College and his Ph.D. in immunology from

the Rockefeller University. Id. He received his medical degree in 2007 and did his post-doctoral training in

Gastroenterology at Columbia Presbyterian Medical Center. Id. Dr. Longman completed a gastroenterology

fellowship in 2013. He is licensed to practice medicine in the state of New York. He has authored or co-authored

numerous medical articles in the field of gastroenterology. Id. at 3-5. He is well qualified to provide an expert

opinion on gastroenterology and immunology.

2

The undersigned held a Rule 5 Status Conference on April 25, 2018, when I observed

that petitioner had a pre-existing history of alopecia, but that it was possible that the ulcerative

colitis may have been caused by an immune reaction to the HPV vaccine. Rule 5 Order at 1-2. I

also observed that petitioner had a treating physician from the Children’s Hospital of Michigan,

indicate that it was a possibility that petitioner had CVID, but thought that petitioner’s

hypogammaglobulinemia would be reversed once her colitis was under control. Id. at 2; see also

Pet. Ex. 2 at 67.

After both parties filed supplemental expert reports from the gastroenterologists and

petitioner filed updated medical records, I held another Rule 5 status conference. See Resp. Ex.

G; Pet. Ex. 20. I noted that petitioner’s diagnosis appeared to be somewhat less clear, especially

as her immune deficiency continued, even after her colitis had resolved. Furthermore, I again

noted that some of petitioner’s medical records suggest that her alopecia, urticaria, warts, and

recurrent sinusitis appeared prior to the vaccinations. Rule 5 Order (ECF No. 94). I posed a

series of questions to petitioner’s experts in the Order.

Petitioner continued to supplement the record with updated medical records, which

included diagnoses from treating physicians. See Pet. Ex. 25. I held another status conference on

January 22, 2020, when I reviewed these records with the parties and observed that petitioner’s

diagnoses included CVID, alopecia areata, inflammatory bowel disease, and others. Scheduling

Order (ECF No. 108). Furthermore, petitioner was also diagnosed with “possible WHIM

syndrome,”6 and chronic urticaria and angioedema. Id. at 2; see also Pet. Ex. 26 at 2099. During

the status conference, petitioner’s counsel stated that petitioner was “narrowing” her claim,

focusing on a significant aggravation of alopecia. Scheduling Order at 2. I indicated that it

would take an additional expert report to “consider how the HPV vaccine stimulated (or

significantly aggravated) an autoimmune condition like alopecia if it is clear that petitioner did

not mount any immune response to the vaccine, as observed by Dr. Savasan. Id. I indicated that

the explanations offered by her previous expert, Drs. Santoro and Glashofer, were not supported

by the medical records, as petitioner continued to suffer from common variable immune

deficiency after her colitis resolved and her alopecia began prior to vaccination. Id.

Petitioner filed a supplemental expert report from Alan F. Cutler, M.D., another

gastroenterologist. Pet. Ex. 28 (ECF No. 119). Dr. Cutler indicated that he disagreed that

petitioner’s CVID was caused by intestinal inflammation, but that petitioner developed

gastroparesis because of the HPV vaccine. Id. at 1-2. I held another status conference with the

parties on July 27, 2021, when I recounted petitioner’s extensive medical history and indicated

that Dr. Cutler’s newest opinion that petitioner developed gastroparesis because of the HPV

vaccine had significant problems. I noted there was no evidence that petitioner had gastroparesis

and by this time petitioner’s diarrhea had resolved and her immunoglobulins remained

essentially undetectable. While both Drs. Santoro and Cutler focused on Dr. Marks’ early

6

WHIM syndrome is a congenital immune deficiency with characteristics clinical features that include Warts,

Hypogammaglobulinemia, recurrent bacterial Infections, and Myelokathexis (apoptosis of mature myeloid cells in

the marrow). Kawai, T. and Malech, H., WHIM Syndrome: Congenital Immune Deficiency Disease, 16(1) Curr.

Opin. Hematol. 20-26 (2009), doi: https://doi.org/10.1097%2FMOH.0b013e32831ac557.

3

hypothesis that the immune deficiency was caused by her diarrhea, Dr. Marks had appropriately

revised her opinion to diagnose agamaglobulanemia not caused by diarrhea.

I recommended that petitioner voluntarily dismiss her petition, however, if petitioner

intended to proceed on this matter, I set a deadline for respondent to file a motion to dismiss.

Scheduling Order (ECF No. 123).

Petitioner decided to continue to proceed with her claim. In the interim, petitioner’s

attorney filed a third motion for interim attorneys’ fees and costs. See Pet. Mot. for Interim

Attorneys’ Fees and Costs (ECF No. 126). I held another status conference in this matter, when I

indicated that “the path to demonstrating entitlement by preponderant evidence seems extremely

unlikely in this matter,” and the medical records demonstrated that petitioner had no response to

the HPV vaccine, or any other vaccines she had received. Id. at 2. Accordingly, I requested that

petitioner file a voluntary dismissal decision, but that if she continues to proceed, respondent will

file a motion for a ruling on the record.

On March 30, 2022, respondent filed a motion for a ruling on the record, requesting that

this petition be dismissed. Resp. Motion (“Mot.”) (ECF No. 139). Petitioner filed a response to

respondent’s motion on August 15, 2022. Pet. Response to Mot. (ECF No. 142). On October 6,

2022, respondent filed a reply to petitioner’s response. Resp. Reply (ECF No. 144).

This matter is now ripe for adjudication.

II. Evidence Submitted

a. Petitioner’s Medical History

i. Medical History Prior to Administration of HPV Vaccine on

February 18, 2013

Petitioner was born on October 10, 1997, at 36 weeks of gestation and weighed 5 pounds

six ounces. Pet. Ex. 2 at 120. She received her regular vaccines, including varicella, hepatitis B,

MMR, TDaP and influenza. Id. at 117. In April 2003, petitioner was admitted to the Children’s

Hospital of Michigan for vomiting and abdominal pain, which was suspicious for a right adrenal

mass. Id. at 121. During her hospitalization, she was noted to have episodic hypertension. Id.

Petitioner had a follow-up appointment with Dr. Neena Gupta on June 2, 2003, after the

hospitalization, at which she noted that petitioner had an esophagogastroduodenoscopy that

showed “mild esophagitis.” Id. It was thought that petitioner’s intermittent blood pressure

elevation was due to anxiety, and it was recommended that she have periodic blood pressure

monitoring. Id. at 122. At a follow-up appointment on July 14, 2003, petitioner’s mother

indicated that petitioner had been taken off of Zantac, and that petitioner’s abdominal pain,

nausea, vomiting, and heartburn subsided. Id. at 119. It was recommended that petitioner can go

back on Zantac if her symptoms flare up again and she can come back to the gastroenterology

clinic as needed. Id.

4

Petitioner had a well visit on October 28, 2004. Pet. Ex. 2 at 118. The note from this

appointment indicates that she had no speech problem and was doing well in general. Id. On

November 5, 2004, petitioner had a consultation with Dr. Robert Rhee for a “bump in the corner

of her left eye.” Id. Petitioner had 20/20 vision in both eyes, but she had a fluid-filled cyst in the

corner of her left eye. Id. Dr. Rhee recommended petitioner to Dr. Christine Nelson at the

University of Michigan, an oculoplastic surgeon for evaluation and treatment. Id. Later the

same month, petitioner had a consultation at the Eye Plastic Orbital and Facial Cosmetic Surgery

Clinic at the Kellogg Eye Center. Id. at 112. Petitioner was diagnosed with a “probable cystic

lesion of the left medial rectus area,” and it was recommended that it be removed and biopsied.

Id. On August 9, 2005, petitioner had the cyst removed from her left eye. Id. at 106.

On August 26, 2009, at age 12, petitioner was admitted to the University of Michigan

Hospital for a three-day history of frequent vomiting and diffuse, crampy, constant abdominal

pain. Pet. Ex. 2 at 95. Prior to admission, petitioner had acute onset of nausea, vomiting and

abdominal pain after camping out during a birthday party, where another child also had nausea

and vomiting. Id. Petitioner was given Visteril, which sedated her, but she continued to vomit

afterwards. The vomiting continued for three days, but only slightly less frequently. Id.

Petitioner had elevated blood pressure and generalized lymphadenopathy. Id. at 97. It was

suspected that her abdominal pain was likely due to gastroenteritis, but considered a “slightly

unusual presentation.” Id. A pelvic ultrasound showed intra-abdominal lymphadenopathy. Id.

Petitioner was discharged three days later, with diagnoses that included, “gastroenteritis,

intermittent hypertension and generalized lymphadenopathy.” Id. at 94.

On January 10, 2011, petitioner had an appointment with her pediatrician for a fever and

swollen neck. Pet. Ex. 9 at 1. Petitioner reported that her jaw hurt, and her head was congested

for a week. Id. She was diagnosed with sinusitis and given a prescription for antibiotics. Id.

Four months later, on April 12, 2011, petitioner was taken back to her primary care for “hives on

and off for one week that were on her arms, legs, and torso.” Id. She was diagnosed with

recurrent urticaria and given a course of prednisone and a prescription for Atarax, an

antihistamine. Id. Approximately two weeks later, on April 25, 2011, petitioner returned to her

primary care provider for the continued rash all over her body. Id. Petitioner was directed to

take Allegra, although her rash was not getting better. Id. The note from this appointment

indicates that her rash was going on for 3-4 weeks with “no known trigger,” and that she did not

have exposure to a cat, dog, or have hay fever. Id. Petitioner’s doctor stated that she should

begin prednisone and take Zyrtec and follow-up in 10-16 days. Id.

Petitioner returned on May 11, 2011 for the follow-up for her hives, which had gone

away and then came back. Pet. Ex. 9 at 2. Petitioner reported that she stayed with her father

who has a dog and her hives returned. Id. Petitioner was also not taking Zyrtec. She was

referred to the allergy clinic at Children’s Hospital.

On June 28, 2011, petitioner had an appointment with Dr. Sahar Faghih at the allergy and

immunology clinic at Children’s Hospital of Michigan. Pet. Ex. 2 at 87. This appointment notes

that petitioner was seen previously on May 31, 2011 for “a complaint of chronic urticaria and

sinusitis.” Id. The record indicates that she completed a course of Augmentin which alleviated

her nasal congestion and pressure, but the Zyrtec did not “significantly improve the occurrence

5

of her hives,” and that she gets them intermittently. Id. Petitioner reported that her hives began

while staying with her father who has two dogs. Id. She was diagnosed with chronic urticaria

and possible dust mite sensitivity. Id. Dr. Faghih’s plan was to do a skin test at the next

appointment. Id. However, no further records from Dr. Faghih or the Allergy and Immunology

Clinic from this time period were filed.

On October 14, 2011, petitioner received a flu shot. Pet. Ex. 9 at 3. She presented for a

sick visit on December 31, 2011 for coughing and green mucus that was present for one week

prior to the appointment. Id. She was diagnosed with sinusitis and given a prescription for

Augmentin and to use a nebulizer at home. Id. at 4.

There are limited medical records between 2011 and November 2012, when there is

another appointment with her primary care provider, when she reported that her right eye hurt

and she noticed that some of her eye lashes were falling out. Pet. Ex. 9 at 5. Petitioner’s mother

expressed some concern about a thyroid issue. Id. Petitioner was given eye drops. She

presented again on January 9, 2013, complaining that her right ear was red and painful, and she

was coughing constantly. Id. at 5. Petitioner was diagnosed with sinusitis and prescribed a

course of antibiotics. Id. She was told to follow-up in 10-14 days. Id. On January 30, 2013,

petitioner again reported coughing and congestion. Id. The nebulizer did not work and she

finished the amoxicillin. Id. Petitioner was diagnosed with acute bronchitis and rhinitis and

given another prescription for amoxicillin. Id. Petitioner returned on February 18, 2013, again

with coughing and congestion, this time her voice was hoarse, and her neck felt swollen. Id. At

this appointment, petitioner wanted to get the HPV vaccine and the vaccine was administered.

She was also diagnosed with bronchitis. Id.

ii. Interim Medical History Between February 18, 2013 and second HPV

Vaccine Administered on April 22, 2013

The next medial appointment in the medical records occurred on April 16, 2013, with Dr.

Steven Grekin, a dermatologist. At this appointment, petitioner had a plantar wart on her right

foot between the 1st and 2nd toes. Pet. Ex. 4 at 6. Importantly, this was a follow-up appointment

which suggests that petitioner had prior appointments with him, however, records from those

appointments were not filed.

Petitioner had an appointment on April 20, 2013 for a runny nose, coughing and green

discharge for five days. Pet. Ex. 2 at 3. Additionally, petitioner’s hives had returned on her arms

and legs. Id. Petitioner was diagnosed with urticaria and acute bronchitis and rhinitis. Id. She

was given a course of prednisone and Azithromycin. Id. Petitioner returned for her second HPV

vaccine on April 22, 2013. Id.

iii. Petitioner’s Medical History After April 22, 2013 to Present

Seven days after her second HPV vaccination, on April 29, 2013, petitioner returned to

her primary care physician for a follow-up of her sinus infection. Pet. Ex. 2 at 3. Petitioner had

finished her antibiotic course; however, her hives were now all over her body. Id. Petitioner

indicated that the hives were coming and going. Id. Petitioner also reported that the cough and

6

congestion was a little better while on the antibiotics, but they came back. Id. Claritin and

Zyrtec were not helpful in controlling the hives either. Id. She was prescribed a fourteen-day

course of Augmentin, another antibiotic. Id.

Petitioner returned to her pediatrician on May 1, 2013 for a follow-up and she indicated

that her hives were improving on the prednisone. Pet. Ex. 2 at 4. Her physician wrote that she

was “unable to determine cause of hives since she had been having recurring hives prior to

getting both antibiotics.” Id. at 4.

On June 12, 2013, petitioner had an appointment with her primary care physician for

coughing, hives (for three months), eye lashes and eyebrows falling out for two months, and

diarrhea for one week. Pet. Ex. 2 at 4. It was noted that petitioner had recurrent hives and that

she had an allergy evaluation, and the cause of the hives was undetermined. Id. Petitioner was

referred to an allergist for another evaluation and diagnosed with recurrent urticaria. Id. Two

weeks later, petitioner reported that she was still having diarrhea twice a day, her left ear was

plugged and she still had hives. Id.

On June 28, 2013, petitioner had a follow-up appointment with her dermatologist for the

plantar warts. Pet. Ex. 4 at 5. There was a note indicating that petitioner had concerns about her

eyelashes and eyebrows falling out for three months. Id. Petitioner also reported that she had

diarrhea for three weeks and a history of ulcerative colitis. Petitioner was diagnosed with

urticaria and alopecia eyebrow. Id.

Petitioner had a consultation at the Gastroenterology, Hepatology, and Nutrition Clinic at

Children’s Hospital of Michigan on July 10, 2013. Pet. Ex. 12A at 22. Petitioner reported that

she was having diarrhea for four weeks, up to six times a day, but decreased. Id. Petitioner also

reported abdominal pain, but the pain resolves once she has a bowel movement. Id. As part of

her medical history, it was noted that petitioner had chronic urticaria and she had been

hospitalized for vomiting when she was five. Id. The plan was for comprehensive blood work

and an upper endoscopy and colonoscopy. Id. at 24. The blood work revealed that petitioner

had extremely low levels of IgA and IgE. Id. at 32.

On July 15, 2013, petitioner had an appointment with Dr. James Fordyce. Pet. Ex. 2 at

73. The reasons for the visit were “chronic urticaria, rhinitis, ear-infection, and diarrhea.” Id.

She was diagnosed with idiopathic urticaria and chronic ear infections, along with chronic

rhinitis. Id. at 75. She was going to have her IgG, IgA, IgM, and IgE tested. Id. Regarding her

diarrhea, Dr. Fordyce considered an inflammatory process, such as Crohn’s disease or functional

bowel issues. Id. Petitioner’s blood work showed that she had nearly no IgE, IgA, IgG or IgM.

Id. at 71.

Petitioner had an endoscopy and colonoscopy on July 18, 2013. Pet. Ex. 2 at 69; Pet. Ex.

12A at 135. The endoscopy revealed a fungal infection in her esophagus, and she was given a

prescription for Diflucan. Id. The colonoscopy revealed diffuse active chronic colitis. Id. at

141. Petitioner had an appointment with gastroenterologist, Dr. Macha on July 24, 2013, to

follow-up from the colonoscopy and endoscopy. Pet. Ex. 12A at 145. Dr. Macha explained that

petitioner had Candidal esophagitis and inflammatory bowel disease, more likely Crohn’s than

7

ulcerative colitis. Id. At a follow-up with Dr. Macha on August 7, 2013, petitioner reported that

her diarrhea was improving, and her abdominal pain and nausea had resolved. Pet. Ex. 12A at

190. Dr. Macha ordered repeat blood work.

On August 5, 2013, petitioner had an appointment with immunologist, Dr. Amy Marks in

the Department of Allergy, Immunology and Rheumatology at the Children’s Hospital of

Michigan. Pet. Ex. 2 at 65. Dr. Marks wrote that petitioner was being seen for

hypogammaglobulinemia.7 Id. Petitioner reported that her hives began two years prior, and they

are chronic but sporadic. Id. Petitioner indicated that she was able to treat them with oral

antihistamines, but approximately six to eight months ago, the hives worsened. Id. at 66.

Additionally, petitioner reported a nine-week history of diarrhea. Id. Dr. Marks wrote that

petitioner had levels of IgA, IgE, IgG, and IgM that were “significantly low.” Id. Dr. Marks

diagnosed petitioner with chronic urticaria, colitis, likely Crohn’s disease,

hypogammaglobulinemia and truncal esophagitis. Id. at 67. Initially, Dr. Marks hypothesized

that petitioner’s hypogammaglobulinemia was likely secondary to her diarrhea and colitis. Id.

Because petitioner was being treated with steroids and Asacol, she wanted to retest her immune

globulins to see if there was improvement. Id. Dr. Marks also wrote that another possibility and

cause is CVID, but wrote, “However, at this time, I do believe this is a secondary

hypogammaglobulinemia that can be reversed once her colitis is under better control.” Id.

Additionally, Dr. Marks also considered whether petitioner’s chronic urticaria could “correlate

with an autoimmune disease, like Crohn’s,” and that petitioner, “likely has autoimmune

urticaria.” Id. at 68. She asked to see petitioner in October. Id.

Petitioner had a follow-up with Dr. Marks on September 25, 2013. Pet. Ex. 2 at 55.

Petitioner’s follow-up blood work once again showed no immunoglobulins, including IgG, IgA

and IgM. Pet. Ex. 2 at 55. Petitioner reported that her diarrhea had subsided, but she was

beginning to show signs of sinusitis. Id. During this visit, petitioner reported to Dr. Marks that

she was experiencing “quite severe plantar warts on her right foot, involving four of the five

toes,” and that she was experiencing flat warts on her face. Id. Dr. Marks wrote, “Again, when

looking back, the warts also started approximately two years ago, which is when [petitioner]

started becoming sick quite regularly with sinus infections, per Mom.” Id. Dr. Marks

recommended that petitioner continue a steroid taper, with her last dose being October 4th. At

this appointment, Dr. Marks wrote, “Given this constellation of symptoms, with complete

agammaglobulinemia, recurrent infections, and warts, I do have some concerns for WHIM

syndrome; however, she does not have the typical variants with abnormalities on CBC and

neutropenia that can be seen.” Id. at 56. Dr. Marks stated that it was “imperative” that petitioner

begin IVIG, given the recurrent infections and constellation of findings. Id. Dr. Marks opined

that petitioner either had “atypical agammaglobulinemia or WHIM syndrome variant.” Id.

Petitioner began receiving IVIG infusions on a monthly basis. See Pet. Ex. 17 at 33; Pet. Ex. 5 at

2; Pet. Ex. 26 at 2093.

7

Hypogammaglobulinemia is abnormally low levels of all classes of immunoglobulins in the blood.

Hyopogammaglobulinemia, Dorland’s Med. Dictionary Online,

https://www.dorlandsonline.com/dorland/definition?id=24235&searchterm=hypogammaglobulinemia (lasted visited

Sept. 22, 2024).

8

Petitioner returned to Dr. Macha on October 30, 2013 for a re-evaluation. Pet. Ex. 12A at

372. Petitioner’s abdominal pain and nausea had subsided. Id. Petitioner also was having

normal bowel movements and was feeling good after two infusions of IVIG. Id. Petitioner was

continuing on Asacol and was “clinically doing well.” Id. A re-evaluation of her GI tract was

recommended after she had completed 3-4 months of IVIG treatment. Id.

On December 5, 2013, petitioner was evaluated by Dr. Sureyya Savasan, a hematologist

in the Department of Hematology and Oncology at the Children’s Hospital of Michigan. Pet. Ex.

2 at 49. Dr. Savasan noted that petitioner experienced four to six weeks of diarrhea before going

to the Gastroenterology Clinic in July 2013. Id. Additionally, she wrote that petitioner has

chronic urticaria which started two years ago and plantar warts involving the inner surfaces of

her toes for the past two years. Id. Further, petitioner reported that she had “a few warts on her

face which currently have subsided.” Id. Petitioner also reported to Dr. Savasan that she had

experienced hair loss that begun “one year ago,” and mainly involves her scalp hair, eyelashes,

and on the upper extremities. Id. Petitioner “noticed a distinct area of hair loss on the right side

of the scalp on the frontal region” and “there is a discrete area of hair loss on the left forearm

which she noticed about five to six weeks ago.” Id. Under “Past Medical History,” Dr. Savasan

recorded that petitioner “has a history of recurrent URI infections since childhood and she has

been treated with several courses of antibiotics periodically for suspected clinical sinusitis;

however, she does not have any documented bacterial or fungal infections.” Id. Dr. Savasan

also observed that petitioner has received all her immunizations, including the two HPV vaccine

doses, but “has not mounted an immune response to the vaccines.” Id. at 51. Dr. Savasan wrote

that petitioner had “almost undetectable levels of immunoglobulins, including IgG, IgA, IgM,

and IgE, her absolute neutrophil count ranged from 2,700-11,000, and her transaminase levels

normalized. Id. Dr. Savasan assessed petitioner with hypogammaglobulinemia with chronic

IVIG infusions, plantar warts, inflammatory bowel disease, history of candida esophagitis, and

alopecia areata. Id. at 53. Dr. Savasan opined that a potential diagnosis of atypical WHIM,

which was being entertained by Dr. Marks, was suspect because her neutrophil levels were

normal and she did not have any serious infections, aside from the repeated upper respiratory

infections. Id. Dr. Savasan wrote that there needed to be further evaluation of petitioner’s

“autoimmune/immunodysregulation condition,” and that additional labs were being ordered,

including T, B and NK cell subset counts, ANA, anti-microsomal antibodies, anti-smooth

antibodies, and anticardiolipin antibody screen “due to the co-existence of immunodeficiency

and autoimmunity and her clinical spectrum.” Id. at 53.8

On December 30, 2013, petitioner returned to Dr. Marks for a re-evaluation of her

hypogammaglobulinemia. Pet. Ex. 2 at 39. Petitioner reported that she was no longer having

diarrhea, but some constipation. Id. Petitioner’s IgG levels were improved, though not normal,

and she was cleared for a repeat colonoscopy in February. Id. Dr. Marks wrote that the antibody

tests ordered by Dr. Savasan may not be significant because petitioner does not produce

antibodies. Id. Dr. Marks also prescribed petitioner cefdinir for 10 to 14 days to combat acute

sinusitis. Id. at 41.

8

It was not clear if these tests were ever done as no additional records with Dr. Savasan were filed, despite having a

follow-up appointment recorded in other medical records. See Pet. Ex. 2 at 42 (noting that petitioner had a follow-

up appointment with Hematology/Oncology on January 16, 2014).

9

Petitioner had an appointment with dermatologist, Dr. Laurie Kohen at the Henry Ford

Hospital on January 3, 2014. Pet. Ex. 6 at 2. Petitioner’s “History of Present Illness” noted that

petitioner had warts on her right foot “ongoing for last 2 years,” and had “numerous liquid

nitrogen cryotherapy treatments over the years without improvement.” Id. Petitioner reported a

“3-month history of patch of hair loss on her right frontal scalp without associated erythema or

pruritus,” and that she had eyelash and eyebrow hair loss. Id. Dr. Kohen wrote that petitioner

“has been undergoing significant medical stressors as she is being worked up for an

immunodeficiency disorder due to findings of absent immunoglobulins all of which began with a

several week history of diarrhea.” Id. A “well-demarcated area of nonscarring alopecia

measuring 4.5 x 3 cm” was located on her right frontal scalp, she also had nonscarring alopecia

on her left eyebrow and left forearm. Id. at 5. Petitioner also had multiple verrucous papules in

the web spaces on her right foot. Id. Petitioner received a Kenalog injection in her scalp and

eyebrow to treat the alopecia. Id. Petitioner was also referred to Dr. Nydorf for bleomycin

injections for the verrucae. Id.

Petitioner had a follow-up appointment with dermatologist, Dr. Kohen, on February 12,

2014. Pet. Ex. 6 at 7. Petitioner reported that she had one “enlarging lesion on her frontal scalp

and a smaller patch adjacent to the larger one,” and that she had yet to use topical steroid on her

scalp. Id. She noted new hair growth in her left eyebrow, but her right eyebrow was now losing

hair. Id. Dr. Kohen administered another Kenalog injections for the scalp lesions and eyebrow

hair loss. Id. at 7.

On March 3, 2014, petitioner had a follow-up appointment with Dr. Marks. Pet. Ex. 2 at

35. Dr. Marks’s diagnosed petitioner with “primary immune deficiency agammaglobulinemia

and chronic urticaria angioedema-autoimmune type.” Id. at 37. Petitioner was to continue IVIG

infusions and continue to be treated by Dr. Kohen for her dermatological issues. Id. On March

25, 2014, petitioner underwent a follow-up colonoscopy and endoscopy. Id. at 26. Dr. Macha

wrote the “EGD demonstrated basal cell hyperplasia in the esophagus and chronic inactive

gastritis in the stomach,” and the colonoscopy demonstrated “chronic enteritis, chronic colitis

with moderate to severe activity in the cecum and ascending colon, and chronic colitis in the

transverse colon.” Id. Petitioner reported no diarrhea, but reduced bowel movements. Id. at 25.

Dr. Macha diagnosed petitioner with pancolitis that was clinically stable, and that petitioner

should continue Asacol twice daily. Id. at 27.

On June 25, 2014, petitioner had a follow-up with the gastroenterology clinic at

Children’s Hospital of Michigan. Pet. Ex. 2 at 25. Petitioner reported that she was eating a

regular diet and was not experiencing any abdominal pain, although she expressed some delayed

bowel movements. Id. It was recommended that petitioner continue Asacol twice daily and to

follow-up in four months. Id. at 27.

Petitioner had a consultation at the Cleveland Clinic on July 23, 2014 with Dr. Joan

Tamburro. Pet. Ex. 5. It was noted that petitioner experienced 12 weeks of diarrhea and it was

initially thought that she had Crohn’s. Id. at 3. Petitioner was experiencing hair loss for 9

months, but her hair loss started prior to the onset of the agammaglobulinemia. Id. The hair loss

began on her eyelashes, then progressed to her scalp, arm hair, and eyebrows. Id. Dr. Tamburro

noted that petitioner was receiving Kenalog injections by Dr. Kohen and using Lidex and

10

Rogaine. Id. Dr. Tamburro also noted that petitioner had been diagnosed with “alopecia totalis.”

Id. Additionally, Dr. Tamburro wrote that petitioner had flat warts on her face that were

spreading. Id. Dr. Tamburro diagnosed petitioner with alopecia areata, verruca plana, verruca

vulgaris, and wrote, “Likely related to agammaglobulinemia or other immune differential

(immunology considering other diagnoses),” and that she would contact Dr. Marks. Id. at 3.

Dr. Tamburro had a phone call with petitioner’s mother and Dr. Marks and indicated that a

follow-up would be beneficial. Id. at 8.

On August 27, 2014, petitioner was seen by Dr. Brian Berman at the Hematology Clinic

at Beaumont Hospital for the possibility evaluation of “possible emerging

leukopenia/neutropenia.” Pet. Ex. 3 at 4. Dr. Berman wrote:

[petitioner] was well until about three years ago when she began to develop recurrent

sinusitis. She received multiple antibiotics and never required hospitalization. At some

point thereafter, she developed a few months of non-bloody diarrhea and substantial

weight process and was placed on Asacol for many months. Her gastrointestinal

symptoms ultimately resolved. About a year ago, she was started on monthly IVIG

infusions because of very significant hypogammaglobulinemia. Subsequently she has

developed widespread alopecia…In addition, she has developed flat warts on her hand as

well as feet.

Id. Dr. Berman wrote that “there is a possibility that she has the WHIM syndrome-warts,

hypogammaglobulinemia, bacterial infections, and myelokathexis. There is also concern that

this may be a variant of common variable immunodeficiency.” Id. He explained, “Over the last

number of months, her blood cell count has been in the 4,000 range with the lowest white count

at 3,300 with an ANC of 1700. Because of the association of neutropenia with WHIM

syndrome, we’ve been asked to evaluate the [petitioner].” Id. Dr. Berman reviewed petitioner’s

labs and noted that her current white blood cell count and neutrophils are adequate and that no

interventions are necessary at this time. Id. at 5. His assessment was:

16 y.o. female with B-cell immunodeficiency, with a history of presumed autoimmune

alopecia and transient inflammatory bowel process associated with propensity toward

papilloma virus. Based on my review of the literature, the possibility of WHIM

syndrome seems very real. Not present is the persistent neutropenia usually associated

with this syndrome (which is related to myelokathexis-apoptosis of [nature] myeloid cells

in the marrow. However, syndromes of this sort may be quite variable in phenotypic

expression.

Id.

On September 22, 2014, petitioner returned to the Cleveland Clinic for a follow-up and

re-evaluation of her alopecia. Pet. Ex. 5 at 11. Dr. Bayart assessed petitioner with alopecia

areata and wrote that “alopecia areata has an unpredictable course, often characterized by periods

of hair loss and regrowth,” and suggested avoiding immunosuppressive therapies if possible. Id.

Dr. Bayart also wrote, “Alopecia areata can be triggered by vaccines (such as Gardasil), but

usually would occur in closer proximity to the vaccination [than] [petitioner’s] alopecia.” Id.

11

Petitioner continued to receive monthly infusions of IVIG and had follow-up

appointments for alopecia, warts, and gastrointestinal issues. See Pet. Ex. 17 at 10. A follow-up

appointment with Dr. Marks on September 26, 2016 indicated that petitioner had one sinus

infection and a follow-up colonoscopy showed no abnormalities. Id. at 33. Petitioner reported

that she was having “significant hair growth” and that her plantar warts had improved. Id. Dr.

Marks’ impression was “19-yo with significant immunodeficiency, agammaglobulinemia,

concern for WHIM syndrome variant, chronic urticaria,” and the plan was for petitioner to

continue to receive monthly IVIG infusions. Id. at 35. Regarding petitioner’s chronic urticaria,

Dr. Marks wrote that she reviewed the pathophysiology and characterized it as “autoimmune in

nature.” Id.

On April 21, 2017, petitioner had an appointment with Dr. Michael Cannon. Pet. Ex. 22

at 2. He recounted her medical history, noting that she was diagnosed with ileocolonic Crohn’s

disease in 2013 and agammaglobulinemia. Id. Petitioner also reported that “all of her symptoms

of hair loss started after the second inoculation for HPV,” and that a “Consultation at Cleveland

Clinic was not definite for a true association with the vaccine.” Id. Dr. Cannon noted that

petitioner “chronic urticaria starting five years prior.” Id. At the time of the appointment,

petitioner was experiencing diarrhea, bloating, and cramping. Id. Dr. Cannon noted that

petitioner’s symptoms “completely resolved on budesonide,” 9and he wanted to wean her off of

it. Id.

Petitioner transferred dermatology care to Dr. Wendy Sadoff and was assessed for

alopecia and plantar warts. Pet. Ex. 24 at 1. Dr. Sadoff wrote, “This is a 19-year-old female

who comes in for a chief complaint of skin lesions, located on the face. The lesions are flat

warts and mild in severity.” Id. Dr. Sadoff removed the flat warts and gave petitioner cream for

her face. Id. Petitioner continued treatment through 2017 Dr. Sadoff. On June 9, 2017, Dr.

Sadoff removed lesions on the right side of petitioner’s face. Id. at 5. The records indicate that

petitioner continued with Dr. Sadoff through 2019 for treatment of both flat warts and alopecia.

See generally Pet. Ex. 24.

On December 17, 2018, petitioner had an appointment with gastroenterologist, Dr. Jared

Bortman after her hospitalization for viral myocarditis where she was also found to be c.diff

positive, but negative toxin Pet. Ex. 22 at 18. Petitioner was treated with antibiotics and her

diarrhea and abdominal pain resolved and she was also taking budesonide. Id. Dr. Bortman

noted that petitioner was taking budesonide every other day and for most of 2018. Id. After

reviewing her history and performing an exam, he wrote that petitioner was “treated for C.diff

diarrhea with Vanco x 2 weeks in 7/2018. Clinically resolved. I am curious as to whether she

truly has Crohn’s disease….Will try to taper off of budesonide.” Id. at 20.

On May 31, 2019, petitioner sought a second opinion from Dr. Carl Lauter. Pet. Ex. 25

at 20. Dr. Lauter wrote that petitioner has a history of IBS, alopecia and agammaglobulinemia

and sought a second immunology opinion and to establish care at the immunology clinic at the

Beaumont Hospital. Id. He wrote that petitioner was in good health in 2013, except for

occasional URIs, isolated congenital cyst removed from the left medial eye corner a wart

removed from her foot. Id. He also noted that petitioner had hives five years prior to 2013 and

9

Budesonide is steroid used to treat Crohn’s Disease

12

it was “attributed to heat and sweating.” Id. Dr. Lauter wrote “she had first shot of HPV in

2/2013. In April 2013 she began having upper respiratory symptoms and hives. Two days later

she received her 2nd dose of HPV vaccine and 3 days later developed bronchitis, rhinitis,

sinusitis, hives, and swollen fingers. She did not get her 3rd dose of HPV vaccine due to her

“reactions.” Id. Dr. Lauter also wrote that “Her hives were attributed to a possible reaction to

Augmentin, however, a month later she continued to have the same symptoms along with loss of

her hair, eyebrows, eyelashes, left ear pain and plugging and new onset of non-bloody diarrhea.”

Id. Regarding her alopecia, Dr. Lauter wrote “[petitioner] denies that her diagnosis was

confirmed as “alopecia areata,” and that she had stopped injections after her hair returned, but

she developed a bald spot in November 2018. Id. at 21. Dr. Lauter observed that petitioner is

followed by Dr. Berman for her thrombocytopenia. Id. He diagnosed her with

agammaglobulinemia, CVID, viral warts, alopecia areata, thrombocytopenia, IBS (unspecified),

and others. Id. at 26. He “agreed with current total management including monthly IVIG,” and

recommended that petitioner do an HPV vaccine test and if negative, complete the HPV series.

Id. Dr. Lauter also wrote that he agrees “with referral to NIH or other major academic center

that has the ability to evaluate complex immune and genetic disorders, such as National Jewish,

Mayo Clinic, University of Cincinnati Children’s Hospital to assess case more thoroughly.” Id.

At a follow-up appointment with Dr. Sadoff, petitioner reported that she was again

experiencing hair loss, however, her verrucous lesions on her face have completely resolved.

Pet. Ex. 24 at 40. Dr. Sadoff noted that Dr. Lauter suggested petitioner participate in an NIH

trial. Id.

Petitioner saw gastroenterologist Dr. Michael Cannon on June 27, 2019 with complaints

of diarrhea. Pet. Ex. 22 at 9. Petitioner reported that she had weaned off budesonide for

approximately 6 months and was doing well until she began to have increased bowel movement

and watery stools. Id. Petitioner restarted budesonide and had “minimal improvement.” Id.

Petitioner was positive for alopecia, sinus drainage, and rhinorrhea. Id. Dr. Cannon diagnosed

petitioner with “diarrhea of presumed infectious origin.” Petitioner was positive for c.diff and

PCR toxin. Id. at 21. He also wrote that he was “in doubt of the diagnosis of Crohn’s disease,”

and that “Agammaglobulinemia does also put her at risk of infectious etiologies, most notably

small intestinal bacterial overgrowth.” Id. Petitioner was to start a course of cephalosporin for

her sinus infection and Dr. Cannon wrote that, “It will be interesting to see if it helps the diarrhea

symptoms.” Id.

Petitioner had a follow-up appointment with Dr. Cannon on September 18, 2019. Pet.

Ex. 22 at 4. At this appointment, petitioner reported that she was treated with Vancomycin after

testing positive for c.diff. Id. Petitioner indicated that she could have up to three days a week

where she experienced diarrhea five times a day. Id. Petitioner was diagnosed with “diarrhea of

presumed infectious origin,” and “indeterminate colitis,” along with CVID and alopecia. Id. at 7.

Dr. Cannon wrote, “last colonoscopy in 2016 was completely normal including small intestine. I

am in doubt of the diagnosis of Crohn’s disease. Agammaglobulinemia does also put her at risk

of infectious etiologies; most notably small intestinal bacterial overgrowth. She unfortunately

developed c.diff after [antibiotic] treatment.”

13

The most recent medical records filed by petitioner indicate that she was still receiving

IVIG infusions at Royal Oak Hospital in March 2020 See Pet. Ex. 27.

b. Expert Opinions

i. Petitioner’s Expert, Dr. Marc Glashofer’s Opinion

Dr. Marc Glashofer, offered his opinion as to how the HPV vaccine could cause a

significant aggravation of alopecia in the petitioner. Pet. Ex. 15. He stated that alopecia areata is

an autoimmune condition in which “an immune response to a component of the hair follicle

leads to loss of hair.” Id. at 4. He wrote that “There is no universally accepted cause, and no

definitive treatment.” Id.

Dr. Glashofer wrote that the purpose of vaccines is to “induce immunity by stimulating a

low-level immune response, such that a subsequent exposure to that immunogen allows the body

to recognize the threat and neutralize it with a robust response, thereby minimizing the

deleterious effects of the microorganism.” Id. He stated that during immunization, “there is the

potential that a portion of the foreign immunogen introduced may have a similar peptide

sequence or be structurally similar to a component of oneself,” and that this leads to “the body

creating an immune response, not just to the introduced antigen, but to normal components of

one’s self, thereby leading to autoimmune reactions and disease states.” Id. at 4-5. Essentially,

he endorsed a theory of molecular mimicry, pursuant to which components of the HPV vaccine

share homology between the structure of hair follicles. He theorized that the immune response to

the vaccine began to target hair follicles, thus exacerbating petitioner’s alopecia.

Dr. Glashofer referenced an article by Chu et al., to support his opinion that a vaccination

can induce alopecia areata. Pet. Ex. 15 at 4. The article is a case report of a young child who

experienced alopecia one week after receiving the third dose of the Japanese encephalitis vaccine

and then again three days after receiving the influenza vaccine. Pet. Ex. 15B at 1.10 The authors

of the article wrote that a review of VAERS case reports found “that patients with the zoster

vaccination or quadrivalent human papillomavirus vaccination had a greater risk of developing

alopecia than unexposed individuals, although the investigators did not have sufficiently detailed

clinical information in either study to ascertain whether each case of “alopecia” was alopecia

areata.” Id. The authors hypothesized that an inflammatory response to the vaccine antigens and

adjuvants could evoke T-cell mediated immune reactions, which can trigger alopecia areata in

genetically predisposed individuals. Id at 2. With respect to the case they were describing, the

authors wrote, “The occurrence of alopecia areata one week after vaccination followed by

regrowth followed by recurrence three days after a different vaccine strongly suggests a link

between vaccination and the onset of alopecia in this child, who was probably genetically

predisposed.” Id.

10

Chu, Chien-Ho, Alopecia Areata after Vaccination: Recurrence with Rechallenge, 33 Pediatric Derm. E218-19

(2016). [Pet. Ex. 15B].

14

Dr. Glashofer also referenced an article by Geier and Geier,11which examined

autoimmune adverse events after HPV vaccination as evidence that alopecia areata can be caused

by the vaccine. The Geier article found that the incidences of “serious autoimmune adverse

events,” including alopecia, “were significantly more likely,” to occur in individuals who

received the HPV-4 vaccine than controls. Pet. Ex. 15C. Geier stated that while the etiology of

autoimmune disease is “still not completely clear… genetic, immunological, hormonal, and

environmental factors are considered to be important triggers,” and that environmental triggers

can include, bacterial, viral or parasitic infections. Id. Furthermore, Geier stated that bacterial,

viral, or parasitic infections are known to induce and exacerbate autoimmune diseases, mainly by

the mechanism of molecular mimicry….it was suggested that the same mechanisms that act in

infectious invasion of the host apply equally to the host response to vaccination.” Id. at 1. The

study indicated that the time between vaccination and onset of symptoms of the adverse

autoimmune event was 6 to 55 days. Id.

Dr. Glashofer concluded his report, stating that “Based on the temporal relationship

between the vaccination and the development of the petitioner’s signs and symptoms of the

disease, there exists a logical sequence of cause and effect, showing that the vaccine resulted in

the petitioner’s injuries.” Pet. Ex. 15 at 4. He wrote that “there are no other non-vaccine

factors,” which appeared to have played a role. Id.

ii. Petitioner’s Expert, Dr. Santoro’s Opinion

In his first report, Dr. Santoro wrote that petitioner developed diarrhea within one month

after receipt of the second HPV vaccination. Pet. Ex. 14 at 6. He stated that petitioner’s initial

diarrhea was caused by the innate immune response, which failed to resolve and progressed to

inflammatory bowel disease, as a result of the later adaptive immune system response. Id. at 7.

Dr. Santoro explained that inflammatory bowel disease is an immune mediated chronic intestinal

condition that can be caused by a combination of factors, including genetics, the environment,

and an overreactive immune system. Id. at 5. Dr. Santoro wrote that there are several case

reports of ulcerative colitis after Gardasil vaccination, which is also an immune mediated chronic

intestinal condition. Id. He noted that in Morgan v. Sec’y of Health & Human Servs., “the

special master found that the petitioner and her experts presented a reasonable theory invoking

the role of both the initial innate response to the vaccine antigen (Gardasil) and of the adaptive

non-specific response as contributing to the development of ulcerative colitis.” Id. at 6; see also

Morgan v. Sec’y of Health & Human Servs., No. 13-529V, 2015 WL 9694667 (Fed. Cl. Spec.

Mstr. Dec. 10, 2015).

Dr. Santoro endorsed a theory of molecular mimicry as a cause of autoimmune disease

post-vaccination. Pet. Ex. 14 at 5. He explained molecular mimicry in general terms, stating,

“Molecular mimicry is one mechanism by which infectious agents (or other exogenous

substances such as vaccines) may trigger an immune response against autoantigens….Molecular

mimicry occurs when a pathogen expresses a protein that is remarkably similar in sequence or

shape to a protein in the host but sufficiently different to provoke an immune response. This can

11

Geier, D. & Geier, M., A case-control study of quadrivalent human papillomavirus vaccine-associated

autoimmune adverse events, 34(7) Clin. Rheumatol. 1225-1231 (2014). [Pet. Ex. 15C].

15

lead to the body creating an immune response...to normal components of one’s self, thereby

leading to an autoimmune reaction and disease.” Id.

In his second report, Dr. Santoro again wrote that the petitioner was “in excellent health

prior to receiving her first Gardasil vaccination on 2/18/2013. Petitioner received her second

HPV4 vaccination on 4/22/2013,” and then developed generalized urticaria, bronchitis, rhinitis

and finger swelling necessitating systemic corticosteroids and within one month of the vaccines

developed diarrhea, and ultimately was diagnosed with inflammatory bowel disease.” Pet. Ex.

20 at 1. He acknowledged that petitioner had significantly low IgA, IgE, IgG, and IgM, which

“would weigh against an excessive auto-immune response,” but opined that petitioner’s

hypogammaglobulinemia was secondary to her severe diarrhea and ulcerative colitis. Id.

Dr. Santoro wrote, “If [petitioner] had genetic IgG deficiency, she would have had a long

history of bronchitis, pneumonia, ear infections, and sinusitis, which is common with such a

deficiency. I did not see any extraordinary such reporting of these problems in [petitioner’s

records].” Id. at 2. He also stated that a review of petitioner’s records did not show that she had

a history of diarrhea, chronic dermatitis, allergic rhinitis, and recurrent infections, thus he did not

believe petitioner had an IgM deficiency prior to receiving the HPV vaccines. Id. Dr. Santoro

wrote, “hypogammaglobulinemia…can be seen in patients with inflammatory bowel disease,

both Crohn’s disease and ulcerative colitis.” Id. at 3. He referenced an article by Elson et al.,

which examined two patients who developed hypogammaglobulinemia secondary to Crohn’s

disease. Pet. Ex. 21.12 The authors acknowledged that “protein-losing enteropathy can be

associated with Crohn’s disease,” but noted that, “this was not the mechanism of

hypogammaglobulinemia in these cases.” Id. at 6. The authors instead found that the patients’

hypogammaglobulinemia was T-cell suppressor mediated, meaning that the T-cells inhibited the

antibody synthesis. Id.

Dr. Santoro stated that petitioner’s treating physician, Dr. Marks, “clearly stated that the

petitioner had ulcerative colitis that explained her low immune globulin levels after the onset of

[petitioner’s] ulcerative colitis.” Pet. Ex. 20 at 3. Dr. Santoro rejected respondent’s expert’s

opinion that petitioner had Common Variable Immune Disorder (“CVID”), stating that Dr.

Marks did not believe that petitioner had CVID, and asserted that petitioner’s IgG levels

improved after several rounds of IVIG and resolution of her gastrointestinal issues. Id. Dr.

Santoro stated that “petitioner does not have a general immunodeficiency disorder or CVID,”

and that it was his opinion that petitioner’s active colitis and diarrhea was the cause of

petitioner’s low levels of immunoglobulins. Id.

iii. Petitioner’s Expert, Dr. Alan Cutler’s Opinion

Petitioner also filed an expert report from another gastroenterologist, Dr. Alan Cutler.

Pet. Ex. 28. Taking a different view as to diagnosis from that of Dr. Santoro, or any of

petitioner’s treating physicians, Dr. Cutler opined that the HPV vaccine caused petitioner to have

gastroparesis, which led to erosive esophagitis. Id. at 3. He stated that without the HPV vaccine,

petitioner “would likely not have developed her upper gastrointestinal symptoms.” Id.

12

Charles O. Elson, et al., Hypogammaglobulinemia Due to Abnormal Suppressor T-Cell Activity in Crohn’s

Disease, 86 Gastroenterology 569-76 (1984). [Pet. Ex. 21].

16

Dr. Cutler also wrote that petitioner was in excellent health prior to the receipt of the

HPV vaccine, ignoring the multiple appointments for sinusitis, bronchitis, otitis and coughing

prior to the receipt of the first vaccine. He said, “within two months of her HPV vaccine, the

petitioner developed a systemic inflammatory reaction including urticaria, bronchitis, rhinitis,

distal extremity edema, and subsequent inflammatory bowel disease.” Id. at 2. He stated,

without citation to the record, that, “petitioner describes stomach problems starting in late

February 2013,” and that she had significant weight loss, reported as 30 pounds, leading to an

investigative endoscopy and colonoscopy which revealed severe erosive esophagitis with

candida and diffuse active chronic pan-colitis. Id. Dr. Cutler wrote that, “The presentation of

significant weight loss with severe esophagitis is commonly seen in gastroparesis, which I

believe contributed to the patient’s presentation and illness.” Id. He explained that gastroparesis

is a syndrome of objectively delayed gastric emptying in the absence of mechanical obstruction.

Presenting symptoms include bloating, nausea, emesis, early satiety and epigastric discomfort

and pain.

Dr. Cutler wrote that he disagreed with Dr. Marks’ finding that petitioner had CVID

caused by intestinal inflammation. Pet. Ex. 28 at 2. Although, he did not discuss the consistent

findings of essentially nondetectable levels of IgG, IgM, IgA and IgE even well after the diarrhea

had ended.

Dr. Cutler explained that gastroparesis presents with symptoms including bloating,

nausea, emesis, feeling full, and epigastric discomfort or pain. Id. at 2. He stated that causes

include, diabetes, autoimmune, post-surgical, viral, neurological disease, or medication induced.

Id. Similarly to Dr. Santoro, Dr. Cutler opined that molecular mimicry could cause petitioner’s

gastrointestinal issues though he diagnosed gastroparesis, writing, “There is a cross-reaction

from a component of the vaccine which results in the loss of immune tolerance and thereby

inappropriate activation of the immune system cells and resulting damage to the gastrointestinal

system. An enteric neuropathy develops due to inflammation and immunologic insult to the

autonomic nervous system.” Id. at 3. He also stated that the adjuvant in the HPV vaccine could

be the cause of the autonomic nervous system insult, instead of just the antigen in the vaccine.

Id. at 2.

Referencing an article by Palmieri et al., which examined reports of neuropathy with

autonomic dysfunction after HPV vaccination, Dr. Cutler asserted that the adjuvant in the HPV

vaccine can cause an autoimmune/inflammatory syndrome induced by adjuvants often referred

to as ASIA. Id.; Pet. Ex. 30.13 The authors explained that an adjuvant is designed to enhance an

immune response to a vaccine, but the theory proposes that the “adjuvants themselves include

some pathogen-associated molecular patterns and/or create a mild tissue injury exposing some

damage-associated molecular patterns, which are recognized by the innate immune system

through specific pattern recognition.” Pet. Ex. 30 at 5. It is the immune response to both the

adjuvant and the antigen that may cause an autoimmune reaction. Id. In their case review, the

Palmieri authors found that many patients reported an “acute phase” of post-vaccination

13

Beniamino Palmieri et al., Severe Somatoform and Dysautonomic Syndromes after HPV Vaccination: Case Series

and Review of Literature, 65 Immunol. Res. 106-16 (2017). [Pet. Ex. 30].

17

symptoms, which include low-grade fever, skin rashes, muscle pain, headache, and sensorial

disturbances. Id. The acute phase onset occurred within hours or days post-vaccination, but then

subsided and patients then began experiencing recurrent or chronic symptoms. Id. The authors

explained that some other studies speculated that post-vaccination fibromyalgia, POTS or

complex regional pain syndrome, might be due to dysfunction in the sympathetic nervous system

caused by the HPV vaccine in susceptible individuals. Id. at 8. Dr. Cutler stated that, “such an

event would explain the development of gastroparesis post-HPV vaccination.” Pet. Ex. 28 at 3.

Dr. Cutler also referenced an article by Brinth et al., as evidence for causation between

the HPV vaccination and the immunologic insult to the autonomic nervous system, including

gastroparesis. Pet. Ex. 28 at 3. In the Brinth article, the authors examined autonomic functions

of patients who had reported autonomic dysfunction symptoms within the first two months of

receiving the HPV vaccine. Pet. Ex. 33.14 They found 53 patients who reported headache,

excessive fatigue, cognitive dysfunction, and widespread neuropathic pain. Id. The authors

diagnosed over half of the patients with POTS, but explained that POTS “should probably be

looked upon as a symptom secondary to another yet unidentified condition rather than as a

disease entity of its own.” Id. While the authors found “a close chronological association to the

vaccination,” they did not opine as to how the vaccine could have caused these symptoms in the

patients. Id.

iv. Respondent’s Expert, Dr. Randy Longman’s Opinion

Dr. Longman wrote two reports for respondent. Resp. Exs. A & G. His reports focused

on both of petitioner’s alleged injuries-an aggravation of her alopecia and the cause of her

gastrointestinal injury.

Dr. Longman responded to Dr. Glashofer’s report, stating, “given the underlying immune

deficiency and hypogammaglobulinemia,” in petitioner, “Gardasil stimulation of immune-

mediated molecular mimicry as suggested by Dr. Glashofer is less likely.” Resp. Ex. A at 4. Dr.

Longman accepted Dr. Glashofer’s explanation of molecular mimicry and wrote that molecular

mimicry has been “described to lead to specific autoantibody response to nerve proteins leading

to Guillain-Barré syndrome.” Id. However, “given the [petitioner’s] primary immunodeficiency

and lack of sustained titers to HBV immunization, it would be more reasonable to suspect a

decreased immune response to Gardasil vaccination rather than stimulating cross-reactive

autoimmune antibodies.” Id. at 4.

Dr. Longman explained that CVID is a primary immunodeficiency characterized by

impaired antibody production and it is the second most common immunodeficiency. Resp. Ex.

A at 3. Clinically, CVID is defined by reduced or absent serum concentrations of IgG, IgA, and

IgM. Id.; Resp. Ex. G at 2. He wrote that the designation “variable” refers to a heterogenous

group of clinical manifestations including recurrent infections, chronic lung disease, and

common gastrointestinal diseases. Id. The hallmark of CVID is the abnormalities in B cell

maturation and differentiation into antibody producing plasma cells. Resp. Ex. G at 2.

14

Louise Brinth et al., Suspected Side Effects to the Quadrivalent Human Papilloma Vaccine, 62 Dan. Med. J. 1-5

(2015). [Pet. Ex. 33].

18

He explained that “IgM is the initial version of the antibody created by the immune system

during the first exposure to antigen.” Id. As the affinity in the antibody is refined, the antibody

type will switch over from IgM to IgG….Low levels of antibodies can result either from

impaired production or increased loss of antibodies. Resp. Ex. G at 1. Impaired production

generally results from abnormalities in B cell maturation and differentiation into memory B cells

that produce antibodies. Id. Hypogammaglobulinemia can also occur due to kidney disease,

burns, or intestinal inflammation. However, in petitioner’s case, even after her inflammatory

colitis resolved, petitioner was still presenting with nearly absent or no antibodies of any class.

See Pet. Ex. 2 at 55-56; Resp. Ex. G at 1.

Dr. Longman explained that petitioner’s presentation of diarrhea which ultimately led to

her diagnosis is consistent with a CVID presentation. He explained that diagnosis is often

delayed following symptom onset. Resp. Ex. A at 5. He referenced and article by Khodadad et

al. article which examined gastrointestinal manifestations in patients with CVID and noted that,

“Some patients [with CVID] may present with GI problems as their first clinical presentation.”

Resp. Ex. D at 5.15 Additionally, the authors stated, “Between 20% and 60% of individuals

develop diarrheal disease, and chronic watery diarrhea is common in CVID.” Id. The authors

noted that “inflammatory bowel diseases appear to occur with increased frequency in patients

with CVID,” but that CVID-associated colitis is “felt to be separate from classic [irritable bowel

disease].” Id. at 5.

Additionally, an Dr. Longman cited to an article by Cunningham-Rundles and Bodian

which explained that the “clinical spectrum of CVID is quite broad, and symptoms of antibody

deficiency may not become obvious until young, middle, or even late in life.” Resp. Ex. I at 1.16

Some patients with CVID may present with classic or, more often, atypical inflammatory

gastrointestinal disease, resulting in diarrhea, malabsorption and weight loss. Id. Furthermore,

the article explained, “For unknown reasons, autoimmune diseases, particularly autoimmune

thrombocytopenia, rheumatoid arthritis, and pernicious anemia, are relatively common in this

patient group.” Id. Acute, chronic, or recurrent infections were found in almost all the cases of

CVID reported in the Rundles and Bodian article, and “almost all the patients had a history of

recurrent episodes of bronchitis, sinusitis, and/or otitis.” Id. at 2.

Dr. Longman observed that petitioner’s treating physician, Dr. Marks, initially

hypothesized that petitioner’s hypogammaglobinemia was related to her active colitis, but noted

that these numbers needed to be reversed once her colitis resolved. See Pet. Ex. 2 at 64.

Importantly, at petitioner’s second appointment with Dr. Marks on September 25, 2013 after her

diarrhea had resolved and she still had “no immunoglobulins, including IgG, IgA, as well as

IgM,” and petitioner’s mother revealed that petitioner had a two year history of chronic sinus

infections, Dr. Marks revised her opinion and diagnosed petitioner with a primary

immunodeficiency of “atypical agammaglobulinemia or WHIM syndrome variant.” Pet. Ex. 2 at

57; Resp. Ex. G at 1. Dr. Longman stated that Dr. Mark’s initial assessment of petitioner was

15

Ahmad Khodadad et al., Gastrointestinal Manifestations in Patients with Common Variable Immunodeficiency,

52 Dig. Dis. Sci. 2977-2983 (2007). [Resp. Ex. D].

16

Charlotte Cunningham-Rundles and Carol Bodian, Common Variable Immunodeficiency: Clinical and

Immunological Features of 248 Patients, 92 Clin. Immunol. 34-48 (1999). [Resp. Ex. I].

19

reasonable and after subsequent evaluation, petitioner’s disease was more consistent with a

primary immune deficiency and was treated as such with IVIG therapy. Resp. Ex. G at 2.

Dr. Longman also observed that petitioner’s experts failed to acknowledged petitioner’s

medical history, which included repeated sinus infections treated with antibiotics, chronic

urticaria, and warts. Resp. Ex. G at 2. In his first report, Dr. Longman reviewed petitioner’s

medical history in detail, chronicling the appointments where petitioner was treated for repeated

sinus infections and recurrent urticaria with antibiotics and steroids. Resp. Ex. A at 1-2. He

opined that the delay in diagnosis, the presentation of petitioner with diarrhea, and the repeated

sinus infections, are all consistent with a primary immunodeficiency, despite no family history of

an immune deficiency or identified genetic disorder to account for her primary immune

deficiency. Resp. Ex. G at 2.

With respect to Dr. Santoro’s opinion that the innate immune system’s response to the

HPV vaccine triggered petitioner’s diarrhea, Dr. Longman stated that “adverse effects of broad

systemic cytokine activation would generally trigger the characteristic biology of fever, change

in blood pressure, leukocytosis, and elevated acute phrase reactants and a general sense of

feeling unwell. These were not present in [petitioner’s] case.” Resp. Ex. A at 4. Dr. Longman

stated that the “non-specific adaptive immune response does not offer a plausible mechanism for

specific intestinal inflammation.” Id. He wrote that, “[Petitioner] tolerated the initial

vaccination without evidence of a non-specific inflammatory response.” Id. He opined that

instead of the vaccine at issue in this case, the temporal association of diarrhea with the use of

antibiotics for persistent upper respiratory infections and congestion is more plausible as a cause

of the diarrhea. Id. at 5. He wrote, “GI manifestations including inflammatory colitis commonly

occur in individuals with CVID and repeated antibiotic exposure increases the potential for

microbial exacerbation of underlying colitis.” Id.

He concluded his reports, stating “petitioner’s presentation is consistent with a primary

immune deficiency such as CVID.” Resp. Ex. G at 3. Dr. Longman wrote, “CVID is a common

primary immune deficiency that can present without family history and is frequently associated

with gastrointestinal inflammation. Therefore, it is my opinion that the petitioner has a primary

immune deficiency, likely CVID, that is causally linked to her history of intestinal

inflammation.” Id.

III. Applicable Legal Standards

To receive compensation through the Program, Petitioner must prove either (1) that she

suffered a “Table Injury”—i.e., an injury listed on the Vaccine Injury Table—corresponding to a

vaccine that she received, or (2) that she suffered an injury that was actually caused by a

vaccination. See §§ 11(c)(1), 13(a)(1)(A); Capizzano, 440 F.3d at 1319-20. Petitioner must

show that the vaccine was “not only a but-for cause of the injury but also a substantial factor in

bringing about the injury.” Moberly, 592 F.3d at 1321 (quoting Shyface, 165 F.3d at 1352-53).

In the present case, petitioner does not allege a Table injury. Instead, petitioner alleges that

she suffered an off-table significant aggravation of her pre-existing alopecia and a new

gastrointestinal injury as a result of the receipt of the HPV vaccination on February 18, 2013 and

20

April 22, 2013. Pet. Response at 21, 26. Thus, petitioner bears the burden of establishing actual

causation of the significant aggravation of these conditions.

a. Causation

Because Petitioner does not allege a Table Injury, she must prove a vaccine she received

actually caused her injury. To do so, Petitioner must establish, by preponderant evidence: “(1) a

medical theory causally connecting the vaccination and the injury; (2) a logical sequence of

cause and effect showing that the vaccination was the reason for the injury; and (3) a showing of

a proximate temporal relationship between vaccination and injury.” Althen, 418 F.3d at 1278.

The causation theory must relate to the injury alleged. Petitioner must provide a sound

and reliable medical or scientific explanation that pertains specifically to this case, although the

explanation need only be “legally probable, not medically or scientifically certain.” Knudsen v.

Sec’y of Health & Hum. Servs., 35 F.3d 543, 548-49 (Fed. Cir. 1994). Petitioner cannot establish

entitlement to compensation based solely on her assertions; rather, a vaccine claim must be

supported either by medical records or by the opinion of a medical doctor. § 13(a)(1). In

determining whether Petitioner is entitled to compensation, the special master shall consider all

material in the record, including “any . . . conclusion, [or] medical judgment . . . which is

contained in the record regarding . . . causation.” § 13(b)(1)(A). The special master must weigh

the submitted evidence and the testimony of the parties’ proffered experts and rule in Petitioner’s

favor when the evidence weighs in her favor. See Moberly, 592 F.3d at 1325-26 (“Finders of

fact are entitled—indeed, expected—to make determinations as to the reliability of the evidence

presented to them and, if appropriate, as to the credibility of the persons presenting that

evidence.”); Althen, 418 F.3d at 1280 (noting that “close calls” are resolved in Petitioner’s

favor).

In determining whether a petitioner is entitled to compensation, a special master must

consider the entire record and is not bound by any particular piece of evidence. § 13(b)(1)

(stating that a special master is not bound by any “diagnosis, conclusion, judgment, test result,

report, or summary” contained in the record). Furthermore, a petitioner is not required to present

medical literature or epidemiological evidence to establish any Althen prong. The special master

essentially must weigh and evaluate opposing evidence in deciding whether a petitioner has met

his or her burden of proof. Andreu, 569 F.3d at 1380; see also Grant v. Sec’y of Health &

Human Servs., 956 F.2d 1144, 1149 (Fed. Cir. 1992).

“Regardless of whether the burden ever shifts to the [R]espondent, the special master

may consider the evidence presented by the [R]espondent in determining whether the [P]etitioner

has established a prima facie case.” Flores v. Sec’y of Health & Hum. Servs., 115 Fed. Cl. 157,

162-63 (2014); see also Stone v. Sec’y of Health & Hum. Servs., 676 F.3d 1373, 1379 (Fed. Cir.

2012) (“[E]vidence of other possible sources of injury can be relevant not only to the ‘factors

unrelated’ defense, but also to whether a prima facie showing has been made that the vaccine

was a substantial factor in causing the injury in question.”); de Bazan v. Sec’y of Health & Hum.

Servs., 539 F.3d 1347, 1353 (Fed. Cir. 2008) (“The government, like any defendant, is permitted

to offer evidence to demonstrate the inadequacy of the [P]etitioner’s evidence on a requisite

element of the [P]etitioner’s case-in-chief.”); Pafford, 451 F.3d at 1358-59 (“[T]he presence of

21

multiple potential causative agents makes it difficult to attribute ‘but for’ causation to the

vaccination. . . . [T]he Special Master properly introduced the presence of the other unrelated

contemporaneous events as just as likely to have been the triggering event as the vaccinations.”).

In Vaccine Act cases, expert testimony may be evaluated according to the factors for

analyzing scientific reliability set forth in Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579,

594-96 (1993); see also Cedillo v. Sec’y of Health & Human Servs., 617 F.3d 1328, 1339 (Fed.

Cir. 2010) (citing Terran v. Sec’y of Health & Human Servs., 195 F.3d 1302, 1316 (Fed. Cir.

1999). In Vaccine Program cases, these factors are used in the weighing of the scientific

evidence actually proffered and heard. Davis v. Sec'y of Health & Human Servs., 94 Fed. Cl. 53,

66–67 (2010) (“uniquely in this Circuit, the Daubert factors have been employed also as an

acceptable evidentiary-gauging tool with respect to persuasiveness of expert testimony already

admitted”), aff'd, 420 F. App'x 973 (Fed. Cir. 2011). The flexible use of the Daubert factors to

determine the persuasiveness and/or reliability of expert testimony in Vaccine Program cases has

routinely been upheld. See, e.g., Snyder v. Sec'y of Health & Human Servs., 88 Fed. Cl. 706,

742-45 (2009).

When both sides offer expert testimony, a special master's decision may be “based on the

credibility of the experts and the relative persuasiveness of their competing theories.”

Broekelschen v. Sec'y of Health & Human Servs., 618 F.3d 1339, 1347 (Fed. Cir. 2010) (citing

Lampe v. Sec’y of Health & Human Servs., 219 F.3d 1357, 1362 (Fed. Cir. 2000)). However,

nothing requires the acceptance of an expert's conclusion “connected to existing data only by the

ipse dixit of the expert,” especially if “there is simply too great an analytical gap between the

data and the opinion proffered.” Snyder, 88 Fed. Cl. at 743 (quoting Gen. Elec. Co. v. Joiner,

522 U.S. 146 (1997)). Weighing the relative persuasiveness of competing expert testimony

based on a particular expert's credibility is part of the overall reliability analysis to which special

masters must subject expert testimony in Vaccine Program cases. Moberly v. Sec’y of Health &

Hum. Servs., 592 F.3d 1315, 1325-26 (Fed. Cir. 2010) (“[a]ssessments as to the reliability of

expert testimony often turn on credibility determinations”); see also Porter v. Sec'y of Health &

Human Servs., 663 F.3d 1242, 1250 (Fed. Cir. 2011) (“this court has unambiguously explained

that special masters are expected to consider the credibility of expert witnesses in evaluating

petitions for compensation under the Vaccine Act”).

b. Significant Aggravation

The Vaccine Act defines significant aggravation as “any change for the worse in a

preexisting condition which results in markedly greater disability, pain, or illness accompanied

by substantial deterioration of health.” § 300aa-33(4). The United States Court of Federal

Claims established the governing six-part test for off-Table significant aggravations in Loving.

Petitioner must prove by a preponderance of the evidence:

(1) The person’s condition prior to administration of the vaccine, (2) the person’s

current condition (or the condition following the vaccination if that is also

pertinent), (3) whether the person’s current condition constitutes a ‘significant

aggravation’ of the person’s condition prior to vaccination, (4) a medical theory

causally connecting such a significantly worsened condition to the vaccination, (5)

a logical sequence of cause and effect showing that the vaccination was the reason

22

for the significant aggravation, and (6) a showing of a proximate temporal

relationship between the vaccination and the significant aggravation.

Loving v. Sec’y of Health & Human Servs., 86 Fed. Cl. 135, 144 (2009); see also W.C. v. Sec’y of

Health & Human Servs., 704 F.3d 1352, 1357 (Fed. Cir. 2013) (adopting this test as the proper

legal standard for significant aggravation claims brought under the Vaccine Act). Loving prongs

four, five, and six are derived from the Federal Circuit’s test for off-Table actual causation cases.

See id. at 143; see also Althen v. Sec’y of Health & Human Servs., 418 F.3d 1274 (Fed. Cir.

2005).

The Federal Circuit clarified Loving prongs 3, 4, and 5 in Sharpe, further defining the

requirements for petitioners to successfully demonstrate a cause-in-fact significant aggravation

claim. Sharpe v. Sec’y of Health & Human Servs., 964 F.3d 1072 (Fed. Cir. 2020). Loving

prong three requires only a comparison of a petitioner’s current, post-vaccination condition with

her pre-existing pre-vaccination condition. Id. at 1082. A petitioner is not required to

demonstrate an expected outcome or that her post-vaccination condition was worse than such an

expected outcome. Id. at 1081.

Loving prong four requires petitioner to provide a “medical theory causally connecting

[petitioner’s] significantly worsened condition to the vaccination.” Id. at 1083 (quoting Loving,

86 Fed. Cl. at 144). In other words, a petitioner is “required to present a medically plausible

theory demonstrating that a vaccine ‘can’ cause a significant worsening” of the condition. Id.

(citing Pafford ex. rel. Pafford v. Sec’y of Health & Human Servs., 451 F.3d 1352, 1356-57 (Fed.

Cir. 2006)). A petitioner may be able to establish a prima facie case under Loving prong four

without eliminating a pre-existing condition as the cause of his significantly aggravated injury.

Id. (citing Walther v. Sec’y of Health & Human Servs., 485 F. 3d 1146, 1151 (Fed. Cir. 2007)

(noting that “the government bears the burden of establishing alternative causation . . . once

petitioner has established a prima facie case”)).

Loving prong five requires a petitioner to show “a logical sequence of cause and effect

showing that the vaccination was the reason for the significant aggravation.” Id. at 1085 (quoting

Loving, 86 Fed. Cl. at 144). In other words, petitioner must show that the vaccination “did” cause

a worsening of petitioner’s underlying disorder. Id. “The sequence of cause and effect is usually

supported by facts derived from petitioner’s medical records. Althen, 418 F.3d at 1478; Andreu

v. Sec’y of Health & Human Servs., 569 F.3d 1367, 1377 (Fed. Cir. 2009); Capizzano v. Sec’y of

Health & Human Servs., 440 F.3d 1317, 1326 (Fed. Cir. 2006). In determining causation, a

special master should consider the causation opinions of the treating providers as “treating

physicians are likely to be in the best position to determine whether ‘a logical sequence of cause

and effect shows that the vaccination was the reason for the injury’” Cappizano, 440 F.3d at

1280.

IV. Discussion

Petitioner is alleging two separate injuries caused by the HPV vaccinations she received

on February 18, 2013, and April 22, 2013. First, she is alleging that the HPV vaccines caused

her to develop gastrointestinal injuries, such as colitis and/or gastroparesis with resultant erosive

esophagitis. See Pet. Exs. 14, 20, &28. Then she is also alleging that the HPV vaccines caused a

23

significant aggravation of her pre-existing alopecia. However, the main problem with both of

petitioner’s claim is rooted in Loving Prong Five/Althen prong two.

a. Loving Prongs One-Three: Discussion and Conclusion

As summarized above, prior to receiving the HPV vaccines, petitioner had been

experiencing hair-loss. See Pet. Ex. 2 at 84, 94-102; Pet. Ex. 4. At least on one occasion,

petitioner reported to her pediatrician that her eye lashes were falling out in 2012. Pet. Ex. 9 at

5. In records that followed the administration of the HPV vaccines, she told treating doctors that

her hair loss began prior to the vaccinations. When petitioner was seen by Dr. Sureyya Savasan,

on December 5, 2013, petitioner reported she “noticed hair loss about one year ago,” and that

“[t]he hair loss mainly involves her scalp hair, eyelashes, and skin on the upper extremities.”

Pet. Ex. 2A at 402-03. Thus, petitioner’s records establish that she had alopecia prior to the HPV

vaccines administered on February 18, 2013 and April 22, 2013, satisfying Loving prong one.

Loving prong two requires a discussion of the petitioner’s “current condition (or

condition following the vaccination if that is also pertinent.” Loving, 86 Fed. Cl. At 144.

Petitioner also has demonstrated that after the vaccinations at issue, her alopecia had changed

and became more widespread. At an appointment with her pediatrician on June 12, 2013, it was

recorded that petitioner had a two-month history of eyebrows and eye lashes falling out. Pet. Ex.

2 at 4. While meeting with Dr. Savasan in December 2013, after the vaccinations, petitioner not

only reported hair loss for one year, but that more recently she had noticed a “distinct area of hair

loss on the right side of the scalp,” and a “discrete area of hair loss on the left forearm which she

noticed about five to six weeks ago.” Pet. Ex. 2A at 403. She continued to report hair loss on

different parts of her body, aside from her eyebrows and eye lashes to multiple providers and

was treated accordingly. See Pet. Ex. 5 at 3; Pet. Ex. 24 at 2. At the time petitioner filed her

responsive brief to respondent’s motion, petitioner still had a diagnosis of alopecia. See Pet. Ex.

24 at 41.17

Loving prong three requires only a comparison of a petitioner’s current or post-

vaccination condition with her pre-vaccination condition. Sharpe v. Sec’y of Health & Hum.

Servs. 964 Fed. Cir. 1072, 1082 (Fed. Cir. 2020); see also Loving, 86 Fed. Cl. at 144. The statute

defines “significant aggravation” as “any change for the worse in a pre-existing condition which

results in markedly greater disability, pain, or illness accompanied by substantial deterioration in

health.” § 33(4). As petitioner acknowledged, she had experienced some hair loss prior to

vaccination and the medical records are clear that her hair loss became more widespread after

receipt of the HPV vaccines, petitioner has demonstrated that there was a change in her hair loss

post-vaccination. Thus, petitioner has established Loving prong three. However, whether the

HPV vaccine was the cause of the change in petitioner’s alopecia is discussed below.

b. Petitioner has not established that the HPV vaccine caused her to develop

gastrointestinal injuries (colitis and/or gastroparesis with resultant erosive

esophagitis) or that it significantly aggravated her pre-existing alopecia.

1. Loving prong four/Althen prong one

17

Respondent concedes that petitioner has satisfied Loving prongs one and two. See Resp. Brief at 18, n. 17.

24

Under Althen prong one, the petitioner must set forth a medical theory explaining how

the received vaccine could have caused the sustained injury. Andreu, 569 F.3d at 1379; Pafford,

451 F.3d at 1355-56. Petitioner’s theory of causation need not be medically or scientifically

certain but it must be informed by a “sound and reliable” medical or scientific explanation.

Boatmon, 941 F.3d at 1359; see also Knudsen, 35 F.3d at 548.

All of petitioner’s experts endorsed a theory of molecular mimicry as a causal mechanism

to explain how the HPV vaccine could cause an aggravation of alopecia and cause different

gastrointestinal injuries. As Dr. Santoro explained succinctly in his first report, “The goal of

vaccination is to induce immunity by stimulating a mild immune response, such that subsequent

exposure to a pathogen, allows the body to recognize the threat and neutralize it with a more

significant response, thereby minimizing deleterious effects of the microorganism.” Pet. Ex. 14

at 6. When explaining molecular mimicry, he states, “There is, however, the potential that a

portion of the foreign immunogen in the vaccine introduced may be structurally similar to a

component of oneself. This can lead to the body creating an immune response, not just to the

introduced vaccine antigen, but to normal components of oneself, thereby leading to an

autoimmune reaction and disease.” Id.

Petitioner’s dermatologic expert, Dr. Glashofer also explained, “During the process of

immunization, there is the potential that a portion of the foreign immunogen introduced may

have a similar peptide sequence or to be structurally similar to a component of one’s self. This

can lead to the body creating an immune response, not just to the introduced antigen, but to

normal components of one’s self, thereby leading to autoimmune reactions….This theory of

autoimmunity is known as molecular mimicry.” Pet. Ex. 15 at 5.

Dr. Longman accepted the petitioner’s experts’ description of molecular mimicry, stating,

“…molecular mimicry is the theoretical possibility that protein molecules from the Gardasil

vaccine can mimic self-peptides that are normally produced by the body, leading to an antigen

specific auto-immune response.” Resp. Ex. A at 3. Dr. Santoro also endorsed an innate

inflammatory response as a causal mechanism for the onset of petitioner’s diarrhea, beginning

roughly forty-four days after she received her second HPV vaccine. Pet. Ex. 14 at 8.

Molecular mimicry has been accepted as a sound and reliable theory to explain how

vaccines, including the HPV vaccine, can result in autoimmune diseases. See Salmins v. Sec’y of

Health & Human Servs., No. 11-140V, 2014 WL 1569478, at *14 (Fed. Cl. Spec. Mstr. Mar. 31,

2014) (finding that the HPV vaccine can cause Guillain-Barre syndrome through a mechanism of

molecular mimicry); Harmon v. Sec’y of Health & Human Servs., No. 12-298V, 2017 WL

2872293, at *23 (finding that molecular mimicry is a reliable causal mechanism for how the

HPV could cause a central demyelinating condition); McCulloch v. Sec’y of Health & Human

Servs., No. 09-293V, 2015 WL 3640610, at *28 (finding that molecular mimicry is a reliable

causal mechanism for how the HPV could cause a seizure disorder). Additionally, I have also

accepted that an inflammatory response to a vaccine by the innate immune system can cause

vaccine-related injuries. See Morgan v. Sec’y of Health & Hum. Servs., No. 13-592V, 2015 WL

9694667 (Fed. Cl. Spec. Mstr. Dec. 10, 2015) (finding that an innate inflammatory response to

the Gardasil vaccine caused petitioner’s ulcerative colitis). However, both theories rest on the

25

assumption that an individual’s immune system will have an immune response, innate and

adaptive, to the vaccine components. Due to the fact that petitioner has an underlying primary

immune deficiency, resulting in no immune response to vaccines she has received, including the

HPV vaccine, my determination as to causation turns on the analysis of Loving Prong

Five/Althen Prong Two.

Due to petitioner’s underlying primary immunodeficiency, the determination as to

vaccine causation turns on Loving prong five/Althen prong two. As I have concluded, as will be

discussed below, that she is unable to satisfy Loving prong five/Althen prong two. Therefore, it is

not necessary to make a Loving prong four/Althen prong one determination. See Winkler v. Sec’y

of Health & Hum. Servs., No. 18-203V, 2021 WL 6276203 (Fed. Cl. Spec. Mstr. Dec. 10, 2021),

mot. for review denied, 2022 WL 1528779, aff’d 88 F.4th 958 (Fed. Cir. 2023) see also Vaughn

ex rel. A.H. v. Sec’y of Health & Hum. Servs., 107 Fed. Cl. 212, 221-22 (2012) (finding the

special master’s failure to rule on Althen prong one was not fatal to his decision because Althen

prong two was fatal to petitioner’s claim); Hibbard v. Sec’y of Health & Hum. Servs., 698 F.3d

1355, 1364 (Fed. Cir. 2012) (“Given that [petitioner] had to show both the medical plausibility of

her theory of causation and that she suffered an injury consistent with that theory of causation,

there was no reason to require the special master to address the first question when the answer to

that question could have no possible effect on the outcome of the case.”) Even if I accepted

petitioner’s theory arguendo, I find that petitioner did not provide preponderant evidence of

logical sequence of cause and effect due to petitioner’s pre-existing primary immunodeficiency

at the time she received the two HPV vaccines in 2013, because she had no immune response to

the vaccines, innate and/or adaptive.

2. Loving Prong Five/Althen Prong Two

Under Loving Prong Five/Althen Prong Two, petitioner must prove by a preponderance

of the evidence that there is a “logical sequence of cause and effect showing that the vaccination

was the reason for the injury.” Capizzano, 440 F.3d at 1324 (quoting Althen, 418 F.3d at 1278).

This prong is sometimes referred to as the “did it cause” test; i.e. in this particular case, did the

vaccine(s) cause the alleged injury. Loving at 144.; Broekelschen, 618 F. 3d at 1345 (“Because

causation is relative to the injury, a petitioner must provide a reputable medical or scientific

explanation that pertains specifically to the petitioner’s case”). “Petitioner must show that the

vaccine was the ‘but for’ cause of the harm…or in other words, that the vaccine was the ‘reason

for the injury.’ ” Pafford, F.3d at 1356.

In this case, petitioner cannot show by preponderant evidence that the HPV vaccines she

received in 2013 was the “but-for” cause of her gastrointestinal injuries or exacerbated her pre-

existing alopecia because of her underlying primary immunodeficiency disorder.

Even though petitioner was not diagnosed with a primary immunodeficiency disease until

approximately five months post-vaccination, petitioner’s pre-vaccination medical history

included signs and symptoms consistent with a course of a primary immunodeficiency described

in the medical literature submitted in this matter, her treating physicians diagnosed petitioner

with common variable immunodeficiency disease, and her medical records revealed nearly

absent levels of antibodies of all classes.

26

The opinions of petitioner’s experts were significantly flawed in two respects. First, they

discounted frequent infections and hives in the year or more prior to her vaccination and made

conclusory statements that petitioner was healthy prior to receiving the HPV vaccines. Second,

petitioner’s experts apparently relied on Dr. Marks’ initial hypothesis that petitioner’s extremely

low immunoglobulin levels were secondary to her prolonged diarrhea while ignoring Dr. Marks’

revised and ultimate opinion that petitioner had a primary immunodeficiency and because of

petitioner’s underlying immunodeficiency disease she had mounted no immune response to the

vaccines.

Common variable immunodeficiency disease is a primary immunodeficiency disease

characterized by reduced serum immunoglobulins. Resp. Ex. I at 1. Reduced levels of of IgG

and IgA and/or IgM, normal or decreased B cell numbers, and impaired antibody response lead

to recurrent infections, noted mostly in the respiratory and gastrointestinal tracts. Resp. Ex. D at

1; see also Resp. Ex. C at 1. While the underlying cause of CVID is unknown, it is described as a

“failure in B cell differentiation, with impaired secretion of immunoglobulins, but T cell

abnormalities, including decreased lymphocyte proliferation to mitogen and antigens, deficiency

of antigen-primed T cells, and reduced production and/or expression of IL-2 and other cytokines

are common.” Resp. Ex. I at 1. There is a high prevalence of gastrointestinal complaints and

issues among CVID patients. Resp. Ex. D at 1. According to the Khodadad article, between

20% and 60% of individuals with CVID develop diarrheal disease, and chronic watery diarrhea

is common in CVID. Resp. Ex. D at 5. “Some patients with CVID present with gastrointestinal

problems as their first clinical presentation, while other develop GI complications during the

course of the disease.” Id. Furthermore, while the esophagus is not commonly involved in

CVID, some patients who are on chronic antibiotics can develop drug-induced esophagitis or

esophageal candidiasis as a side effect of the antibiotics. Id.

According to the Cunningham and Rundles article, there is approximately a 4–6-year lag

time between when symptoms initially occur and the diagnosis of CVID is made. Resp. Ex. I at

11. Because patients with CVID present with varied illnesses, including gastrointestinal issues

or recurring respiratory infections, they are treated by multiple physicians, which can delay

recognition of the antibody deficiency. Id. at 1. Standard treatment for CVID is periodic IVIG

infusions. Id. at 2.

Prior to receiving the two HPV vaccinations in 2013, between January 2011 and February

2013, petitioner was treated for multiple sinus infections and given multiple courses of

antibiotics for treatment. See Pet. Ex. 9 at 2 (January 10, 2011: diagnosed with sinusitis and

prescribed Amoxicillin for ten days); Pet. Ex. 2 at 84 (May 31, 2011: Patient is status post-

treatment of 21 days of Augmentin which she states alleviated her nasal congestion and pressure

significantly. She also states that starting Zyrtec did not seem to significantly improve the

occurrence of her hives.); Pet. Ex. 9 at 4 (December 31, 2011: 14-year old with a history of

prolonged sinus infection over the spring and summer that caused hives, took an antibiotic for 3-

4 weeks until it resolved); Pet. Ex. 9 at 6 (January 9, 2013: patient has painful right outer ear,

also coughing and congested with yellowish sinus drainage four times a day. Diagnosed with

sinusitis and was prescribed a course of Amoxicillin for ten days); Pet. Ex. 9 at 6 (January 30,

2013: patient is coughing with congestion, did not finish Amoxicillin. Diagnosed with bronchitis

27

and rhinitis, prescribed Azithromycin, an antibiotic); Pet. Ex. 9 at 7 (February 18, 2013: Horse

voice and neck feels swollen for two days, finished Z-pack); Id. at 8 (April 20, 2013: patient has

runny nose, coughing, and green discharge for five days. Diagnosed with bronchitis and rhinitis

and gave another Z-pack); see also Pet. Ex. 9 at 7 (April 29, 2013: bronchitis and rhinitis sinus

infection and hives all over body. Persistence of congestion and coughing. Given a course of

Augmentin for fourteen days).

Despite this extensive history of chronic and recurrent sinus infections, petitioner’s

experts contended that petitioner did not have recurrent infections or at least that she did not have

an extraordinary history of infections. Dr. Santoro wrote, “If the patient had a genetic IgG

deficiency, she would have had a long history of bronchitis, pneumonia, ear infections and

sinusitis, which is common with such a deficiency. I did not see any extraordinary such

reporting of these problems in [petitioner’s] records.” Pet. Ex. 20 at 3 (emphasis added). Dr.

Santoro also suggested that if there had been a historical problem that pre-dated the vaccinations,

petitioner would have already been treated with IVIG.

However, as explained by Dr. Longman and supported by the Cunningham-Rundles

article, delay in diagnosis of CVID is common because patients present with an array of illnesses

to multiple physicians. See Resp. Ex. G at 2; Resp. Ex. I at 1. Even though petitioner was not

diagnosed with a primary immunodeficiency until September 2013, prior to her diagnosis, she

was treated by multiple doctors for different issues, including urticaria, chronic sinusitis,

bronchitis, warts, and prolonged diarrhea as recounted above. In 2013, petitioner had multiple

trips to her primary pediatrician between January and July for chronic sinus infections with

prolonged treatment with antibiotics. See Pet. Ex. 9 at 7-8 (4/29/13: review bronchitis and

rhinitis, sinus infection; hives all over body; persistent congestion, cough, and sinus headache, a

little better on antibiotics but came back; still having hives over entire body; 5/1/13: Follow-up:

reaction to Augmentin? Hives all over; swollen fingers; currently on prednisone; 6/12/13:

coughing, hives for three months, diarrhea for one week, refer for allergy evaluation; 6/24/13:

still has diarrhea twice a day, left ear hurts, wax in both ears, urticaria resolved, prescribed

Azithromycin; 7/2/13: still has diarrhea, third visit since 6/12/13, refer to GI-CHM, CBC

normal).

Even with her prolonged diarrhea which began in June 2013, it was not until July 15,

2013, when allergist-immunologist Dr. James Fordyce recommended that petitioner have her

antibody levels were tested. Pet. Ex. 2 at 79. On July 19, 2013, petitioner’s antibody tests

revealed significantly low IgA (less than 8 mg/dl), significantly low IgE (less than 2 IU/ml), low

IgG serum of 70 mg/dL, and low IgM. Pet. Ex. 2 at 72. It was then petitioner was referred to

Dr. Marks of immunology for the concerning low levels of antibodies.

Petitioner’s treating physicians also acknowledged petitioner’s history of recurrent

infections when diagnosing her with a primary immunodeficiency. At petitioner’s second

appointment with Dr. Marks on September 25, 2013, petitioner’s mother reported that petitioner

had been experiencing severe warts and regular sinus infections that began two years prior. The

exact note from this appointment states:

28

She did call to my attention, which we did not discuss at our last visit, that [petitioner]

has been experiencing quite severe plantar warts on her right foot, involving four of the

five toes. In addition to this, she has been experiencing warts on her face. Again, when

looking back, the warts also started approximately two years ago, which is when

[petitioner] started becoming sick quite regularly with sinus infections, per Mom.

Pet. Ex. 2 at 56 (emphasis added). Dr. Marks opined, “Given this constellation of symptoms

with complete agammaglobulinemia, recurrent infections, and warts, I do have some concerns

for WHIM’s syndrome; however, she does not have the typical variants with abnormalities on

CBC with neutropenia that can be seen.” Id. at 57. Additionally, when petitioner was evaluated

by Dr. Brian Berman one year later, on August 27, 2014, he wrote that petitioner “was well until

three years ago when she began to develop recurrent sinusitis. She received multiple antibiotics

and never required hospitalization.” Pet. Ex. 3 at 5. The evidence that petitioner had repeated

sinus and bronchitis infections treated with antibiotics is incontrovertible and is consistent with

the diagnosis of a primary immune deficiency.

Dr. Santoro also argued that petitioner’s agammaglobulinemia was caused by

inflammatory colitis and wrote, “Dr. Mark’s opinion clearly stated that the petitioner had

ulcerative colitis that this explained her low immune globulin levels after the onset of her

ulcerative colitis and diarrhea, but not before,” and, “[Dr. Marks] was of the opinion that

[petitioner] did not have CVID.” Pet. Ex. 20 at 4. While Dr. Santoro is correct that when Dr.

Marks first met with petitioner on August 5, 2013, she considered that petitioner was losing

“immunoglobulins of all classes through her stools,” but also cautioned that she wanted to do

repeat blood work after a few weeks of treatment of colitis with Asacol to see if her levels

rebounded. See Pet. Ex. 2 at 65. When petitioner returned to Dr. Marks on September 25, 2013

and petitioner’s diarrhea had subsided, she again noted that petitioner had “no immunoglobulins,

including IgG, IgA, as well as IgM.” Id. at 56. Dr. Mark’s opined after this appointment

“atypical agammaglobulinemia or WHIM syndrome variant.” Id. At the November 4, 2013

follow-up with Dr. Marks, petitioner’s diagnosis was “primary immune deficiency, recurrent

infection, and agammaglobulinemia.” Pet. Ex. 12A at 472. At petitioner’s appointment with Dr.

Savasan in December 2013, again she had “almost undetectable levels of immunoglobulins,

including IgG, IgA, IgM, and IgE.” Pet. Ex. 2A at 405. When Dr. Berman met with petitioner,

he aptly diagnosed her with “B-cell immunodeficiency, with a history of presumed autoimmune

alopecia and transient inflammatory bowel process associated with propensity toward papilloma

virus,” and that “the possibility of WHIM syndrome seems very real.” Pet. Ex. 3 at 6. Thus, the

medical records do not support Dr. Santoro’s assertions that petitioner’s agammaglobulinemia

was secondary to her diarrhea, as her immune deficiency continued well after resolution of her

diarrhea. Ultimately, Dr.Marks, Dr.Savasan and later Dr. Lauter and Dr. Berman diagnosed

CVID and Dr. Marks and Savasan noted that petitioner had not mounted an immune response to

the vaccines that she had received also consistent with CVID.

With respect to petitioner’s alopecia, aside from her condition worsening after she

received the two HPV vaccines and that alopecia areata is considered an autoimmune condition,

petitioner’s expert, Dr. Glashofer’s opinion rested entirely on the assumption that petitioner had

a reaction to the HPV vaccine. See Pet. Ex. 15 at 5 (“…the Gardasil vaccination set off a

reaction of inducing various disease states of autoimmunity in the petitioner.”). The medical

29

literature Dr. Glashofer referenced to support his opinion did little to advance petitioner’s

argument that the HPV aggravated her alopecia. The Chu et al. article is a case report of young

child developing alopecia within one week of receiving a vaccine different from the HPV

vaccine. Pet. Ex. 15B at 3. The Geier and Geier article is a review of VAERS data of adverse

events post Gardasil vaccination, which provides evidence of increased reporting of diagnoses of

alopecia post-HPV vaccination. However, even if these articles provided any mechanistic

evidence which they do not, they suffer from the same problem as other general articles on the

subject as applied to the present case in that it does not provide any evidence of causation in a

person with a severe immune deficiency such as that suffered by the petitioner.

Petitioner also argues that Dr. Tamburro, a physician at the Cleveland Clinic, associated

the Gardasil vaccine with the onset or change in petitioner’s alopecia. Pet. Response at 26. This

mischaracterizes the medical records from Dr. Tamburro. At petitioner’s first appointment with

Dr. Tamburro on July 23, 2014, Dr. Tamburro noted that petitioner’s hair loss began prior to her

diagnosis of agmmaglobulinemia in August 2013. Pet. Ex. 5 at 3. She also noted that petitioner

had viral warts. Id. After an examination, Dr. Tamburro diagnosed petitioner with alopecia

areata, verruca plana, and verruca vulgaris and wrote, “likely related to agammaglobulinemia or

other immune differential.” Pet. Ex. 5 at 4 (emphasis added). At the follow-up appointment on

September 22, 2014, petitioner reported that her alopecia had worsened. Id. at 11. She

documented multiple spots of hair loss in the frontal, parietal and occipital areas of the head as

well on various other locations on her body. Dr. Tamburro diagnosed petitioner with alopecia

areata and noted that it has “an unpredictable course.” Id. at 12. Dr. Tamburro also wrote,

“Alopecia areata can be triggered by vaccines (such as Gardasil), but usually would occur in

closer proximity to the vaccination [than] [petitioner’s] alopecia.” Id. While Dr.Tamburro

apparently answered a question about Gardasil causation of alopecia, refencing possible general

vaccine causation, her opinion was that petitioner’s condition was more likely related to

agammaglobulinemia. This view is supported by the Cunningham-Rundles article, which notes,

“For unknown reasons, autoimmune diseases, particularly autoimmune hemolytic anemia,

autoimmune thrombocytopenia, rheumatoid arthritis, and pernicious anemia, are relatively

common in this patient group.” Resp. Ex. I at 1. Thus, the general statement of Dr. Tamburro

associating alopecia causation to vaccines is not sufficient to overcome the overwhelming

evidence that petitioner had a primary immunodeficiency disease that was more likely the cause

of her alopecia, considering she had no response to the HPV vaccine or other vaccines she had

received in the past.

Petitioner cannot show how the theories posited by her experts, which assume activation

of petitioner’s immune system, could cause autoimmune injuries, in the absence of an immune

response to the HPV vaccine. Even if I had accepted any of petitioner’s experts’ theories as to

vaccine causation of gastrointestinal disease or alopecia areata, there would be no logical

sequence of cause and effect because petitioner did not have an immune response to the HPV

vaccine, or any vaccine for that matter.

Petitioner’s bloodwork included testing for antibodies against tetanus and diphtheria,

which showed no antibodies to either antigen despite receiving multiple vaccines containing the

two antigens. Pet. Ex. 2 at 12. At petitioner’s appointment on November 3, 2013, petitioner and

her mother discussed getting a flu vaccine with Dr. Marks and Dr. Marks explained, “there is no

30

reason that we cannot give her [a flu shot], but I do not think she will amount much of a response

given her immune system at this time.” Pet. Ex. 12A at 472. On the December 6, 2013

appointment record with Dr. Savasan, the “Immunization Status,” section states, “[petitioner]

received all of her immunizations, receiving two of the three doses of Gardasil; however,

[petitioner] has not mounted an immune response to vaccines.” Pet. Ex. 2 at 46; Pet. Ex. 12A at

404. These statements by Dr. Marks and Dr. Savasan are unequivocal. Not only did petitioner

not have an immune response to the HPV vaccines or tetanus/diphtheria, she had repeated blood

work that showed immunoglobulins were undetectable. There is no evidence that petitioner had

any type of immune reaction to the HPV vaccines, either an innate or adaptive, without which it

difficult to see how the vaccine could have caused a cross reaction giving rise to any of the

various conditions claimed by petitioner particularly given that they were more likely explained

by her CVID.

Evidence of other possible sources of injury can be relevant not only for the “factors

unrelated” defense, but also as to whether prima facie showing has been made that the vaccine

was a substantial factor in causing the injury in question. Stone v. Sec’y of Health & Hum.

Servs., 676 F.3d 1373, 1379 (Fed. Cir. 2012); see e.g. de Bazan v. Sec’y of Health & Human

Servs., 538 F.3d 1347, 1353 (Fed. Cir. 2008) (“The government, like any defendant, is permitted

to offer evidence to demonstrate the inadequacy of the petitioner’s evidence on a requisite

element of petitioner’s case-in-chief.”). “In some cases, a sensible assessment of causation

cannot be made while ignoring the elephant in the room—the presence of compelling evidence

of a different cause for the injury in question.” Stone, F.3d at 1380 (citing Walther, 485 F.3d at

1151 n.4). Here, the elephant in the room is petitioner’s underlying primary immunodeficiency

disease that serves as compelling evidence of a different cause of her alleged injuries, and she

cannot show that the HPV vaccinations were the but-for cause of her gastrointestinal illnesses or

significant aggravation of her alopecia.

For the reasons discussed above, I find that petitioner has failed to provide preponderant

evidence of a local sequence of cause and effect required under Loving prong five/Althen Prong

Two.

3. Loving Prong Six/Althen Prong Three

The final Loving prong requires petitioner to establish a “proximate temporal

relationship” between the significant aggravation of his condition and the received vaccine.

Loving 86 Fed. Cl. at 144; see also Althen, 418 F.3d at 1281. That term has equated to the

phrase, “medically-acceptable temporal relationship.” Althen at 1281. A petitioner must offer

“preponderant proof that the onset of symptoms occurred within a timeframe which, given the

medical understanding of the disorder’s etiology, it is medically acceptable to infer causation.”

de Bazan v. Sec’y of Health & Human Servs., 539 F.3d 1347, 1352 (Fed. Cir. 2008). The

explanation for what is a medically acceptable timeframe must also coincide with the theory of

how the relevant vaccine can cause an injury (Althen prong one). Id. at 1352.

The explanation for what is a medically acceptable time frame must also coincide with

the theory of how the relevant vaccine can cause the injury alleged (under Althen Prong One).

Id.; Koehn v. Sec’y of Health & Hum. Servs., 773 F.3d 1239, 1243 (Fed. Cir. 2014); Shapiro, 101

31

Fed. Cl. at 542; see also Pafford, 451 F.3d at 1358. A temporal relationship between a vaccine

and an injury, standing alone, does not constitute preponderant evidence of vaccine causation.

See, e.g., Veryzer, 100 Fed. Cl. at 356 (explaining that “a temporal relationship alone will not

demonstrate the requisite causal link and that [P]etitioner must posit a medical theory causally

connecting the vaccine and injury”).

Based on petitioner’s medical records, the onset of petitioner’s gastrointestinal illness

began in or around June 6, 2013, approximately forty-four days after she received her second

HPV vaccine on April 22, 2013. Petitioner’s expert, Dr. Santoro opined that this timeframe is

medically appropriate for an innate inflammatory response to the vaccine and referenced

Morgan, an HPV-ulcerative colitis case. However, aside from the fact that petitioner’s

underlying primary immunodeficiency disease caused her to have no immune response to the

HPV vaccine, inflammatory or adaptive, the facts and expert opinion in Morgan differ

significantly from this one. The onset of petitioner’s gastrointestinal symptoms in Morgan began

six-hours after the HPV vaccination, became continuous, she needed extensive surgical resection

of her colon, and there was no alternative explanation for the onset of petitioner’s symptoms.

Morgan, 2015 WL 9694667, at *15. Further, the expert in Morgan, her gastrointestinal surgeon,

opined that the vaccine triggered an initial innate inflammatory response and that the cytokines

from the innate response signaled an adaptive immune response causing the autoimmune

condition of ulcerative colitis. Id. In contrast, the onset of petitioner’s diarrhea in this case was

forty-four days after petitioner received the second HPV vaccine on April 22, 2013 and largely

resolved with medication, which is more consistent with a gastrointestinal illnesses secondary to

a primary immunodeficiency disease. See Resp. Ex. D at 5 (“Some patients may present with GI

problems as their first clinical presentation, while other develop GI complications during the

course of the disease.”); see also Resp. Ex. C at 3 (“Often, in these patients, appearance of

Crohn’s-like inflammatory bowel disease findings in the intestine supports immunodeficiency

findings that are triggered by infections of inflammatory bowel disease etiology.”). Thus, the

onset of petitioner’s diarrhea forty-four days post-vaccination is significantly more consistent

with a condition incident to common variable immune deficiency.

The date of onset of the worsening of petitioner’s pre-existing alopecia is more uncertain

than the date of onset of her gastrointestinal illness, aside from it happening sometime after the

second HPV vaccination she received on April 22, 2013. Petitioner reported to Dr. Savasan in

December 2013 that she was experiencing hair loss on her scalp and at her appointment with Dr.

Berman, petitioner described developing “widespread alopecia” after she was started on IVIG

infusions. See Pet. Ex. 12A at 403; Pet. Ex. 3 at 5. Further, one of petitioner’s treating

physicians, Dr. Tamburro suggested that the onset of petitioner’s alopecia, or worsening of her

alopecia, occurred too long after the HPV vaccination. See Pet. Ex. 5 at 12. The medical records

would put the onset of petitioner’s alopecia becoming worse approximately four to six months

post-vaccination, which would exceed what has been considered an acceptable medical

timeframe to infer vaccination causation. Thus, petitioner has failed to satisfy Loving Prong

Six/Althen Prong Three.

32

V. Conclusion

After a careful review of the record, petitioner has failed to provide preponderant

evidence that her gastrointestinal illness or her alopecia were caused by or were significantly

aggravated by the HPV vaccines she received on February 18, 2013, and April 22, 2013.

Accordingly, petitioner’s claim is hereby DISMISSED.

IT IS SO ORDERED.

s/Thomas L. Gowen

Thomas L. Gowen

Special Master

33